Nanocomposites of Layered Clays and graphene/graphene oxide for drug delivery by Hegazy, Nada Mahmoud
American University in Cairo 
AUC Knowledge Fountain 
Theses and Dissertations 
2-1-2015 
Nanocomposites of Layered Clays and graphene/graphene oxide 
for drug delivery 
Nada Mahmoud Hegazy 
Follow this and additional works at: https://fount.aucegypt.edu/etds 
Recommended Citation 
APA Citation 
Hegazy, N. (2015).Nanocomposites of Layered Clays and graphene/graphene oxide for drug delivery 
[Master’s thesis, the American University in Cairo]. AUC Knowledge Fountain. 
https://fount.aucegypt.edu/etds/215 
MLA Citation 
Hegazy, Nada Mahmoud. Nanocomposites of Layered Clays and graphene/graphene oxide for drug 
delivery. 2015. American University in Cairo, Master's thesis. AUC Knowledge Fountain. 
https://fount.aucegypt.edu/etds/215 
This Thesis is brought to you for free and open access by AUC Knowledge Fountain. It has been accepted for 
inclusion in Theses and Dissertations by an authorized administrator of AUC Knowledge Fountain. For more 
information, please contact mark.muehlhaeusler@aucegypt.edu. 
The American University in Cairo 
School of Science and Engineering 
Nanotechnology Graduate Program 
 
Nanocomposites of Layered Clays and 
graphene/graphene oxide for drug delivery  
 
A thesis submitted in partial fulfillment of the requirements for the 
degree of  
Master of Science in Nanotechnology  
 
By Nada Mahmoud Hegazy 
 
Under the supervision of 
Prof. Adham Ramadan 
 
Fall 2015 
 
II 
 
The American University in Cairo 
Nanocomposites of Layered Clays and 
graphene/graphene oxide for drug delivery  
A Thesis submitted by 
Nada Mahmoud Hegazy 
To the Nanotechnology Graduate Program 
Fall 2015 
A thesis submitted in partial fulfillment of the requirements for the degree of 
Master of Science in Nanotechnology 
Has been approved by 
Thesis Committee Supervisor /Chair: Dr. Adham R. Ramadan 
Affiliation: Professor of Chemistry and Dean of Graduate Studies, the American 
University in Cairo. 
 
Thesis External Examiner: Dr. Omaima N. El Gazayerly 
Affiliation: Professor and Chair of the Pharmaceutics and Industrial Pharmacy 
Department, Faculty of Pharmacy, Cairo University. 
 
Thesis Internal Examiner: Dr. Wael Mamdouh 
Affiliation: Assistant Professor of Chemistry, Chemistry Department, School of Sciences 
and Engineering, the American University in Cairo. 
 
Thesis Committee Moderator: Dr. Mayyada El Sayed  
Affiliation: Visiting Assistant Professor of Chemistry, Chemistry Department, School of 
Sciences and Engineering, the American University in Cairo. 
  
Program Director                                  Date                                  Dean                                         Date 
  
III 
 
Acknowledgment 
Research work was a significant experience for me, not only on the academic level, but 
also on the personal level. It has added to my research experience, and added to my circle 
of acquaintances. 
First of all, I would like to thank my big family: parents, grandparents, sister, brother, 
aunt, and uncles. Each one of them provided me with emotional support, they were 
patient and standing out there for me all along. Their prayers and encouraging is what 
sustained me that far. 
A special appreciation and sincere gratitude to my advisor Prof. Adham Ramadan, for 
being a tremendous mentor and for his continuous support, patience, and immense 
knowledge. His guidance helped so much throughout the research, and am really grateful 
to him for accepting me to work under his supervision. 
My sincere gratitude to the huge technical support, provided by Mr. Mahmoud Abdel 
Moez, and Mr. Emad Farag. I am also very grateful to Mr. Ahmed Omaya for being a 
supportive friend in my research work and for facilitating a lot of technicalities. Without 
their help, I wouldn’t have conducted this work. 
I would like to acknowledge the support of my graduate professors, their educational 
material and advices.  
Last but definitely not least, my colleagues who turned to be best friends ever, who made 
this experience more fun and smooth. Words are not enough to express how supportive 
they were throughout my research work, career and on a personal level. Thanks for each 
and every one of them: Zahraa, Raghda, Alshaima, Yomna, Ruaa and Woroud. 
    
 
 
 
 
 
IV 
 
LIST OF ABBREVIATIONS  
Abbreviation Meaning 
ALG Alginate  
BP Benzyl penicillin 
BSA Bovine serum protein 
CD44 Cluster determinant  
CS Chitosan  
Cy Cytamine  
DA Dopamine  
DLS Dynamic light scattering 
DNA Deoxy ribonucleic acid 
DO Dicetyl phosphate 
DOX Doxorubicin  
FA Folic acid 
FPP Farensyl diphosphate synthase 
FT-IR Fourier transform infrared  
G Graphene 
GBMs Graphene based materials 
GIT Gastro-intestinal tract 
GO Graphene oxide 
GSH Glutathione  
GTPase Guanosine triphosphate 
HA Hyaluronic acid  
I.V. Intravenous  
IR  Infrared  
KBr Potassium bromide 
LDH 
LDV 
Layered double hydroxide 
Laser Doppler velocimetry 
nBPs Nitrogen containing bisphosphonates  
NGO Nano-carrier graphene oxide 
NSAIDS Non-steroidal anti-inflammatory drugs  
PAA Polyacrylic acid 
PEG Polyethylene glycole  
rGO Reduced graphene oxide 
ROS Reactive oxygen species  
SA Stearyl amine 
SEM Scanning electron microscope 
SGF Simulated gastric fluid  
SLNs Solid lipid nanoparticles 
TMC Trimethyl chitosan  
U.V Ultraviolet 
USP United state pharmacopeia  
Vis Visible 
XRD X-ray diffraction  
V 
 
ABSTRACT 
Layered double hydroxides (LDH) comprise a class of materials that can be either found 
as natural minerals or can be synthetically prepared. Their structure is composed of a 
mixture of divalent and trivalent metal cations, forming brucite-like layers, that are 
neutralized with anions in the interlayer gallery. They have unique physical and chemical 
characteristics such as: high surface area, large charge density, biocompatibility and 
exchange capacity. These have attracted attention to the LDHs as potential drug delivery 
vehicles.  
Graphene (G) has also attracted the attention to exceptional properties, such as huge 
surface area, charge density concentration, membrane permeability by piercing 
mechanism and many others, expanding its use to include biomedical applications, such 
as drug delivery. Moreover, the possibility of large scale production of exfoliated 
graphene oxide (GO) sheets from G offered a further opportunity for their use. GO has a 
high exposed oxygenated surface that allows loading of large number of drugs by 
different bonding interactions and is dispersible in water.  
Alendronate sodium is a water soluble nitrogen containing bisphosphonate (nBP) drug, 
that has low bioavailabilty (< 1 %) due to its low epithelial permeability. It also exhibits 
gastrointestinal adverse effects.  
The objective of the work is to create a hybrid nanocomposite of Zn-Al LDH in its nitrate 
form with G/GO, (G/GO-Zn-Al-NO3 LDH), combining the properties of these structures:  
membrane permeability and large interacting surface of G or GO, the buffering effect and 
the  capability of the LDH in storing and controlling the drug release. The hybrid 
nanocomposites incorporated 2% w/w of G or GO with two different M
2+
/M
3+
 ratios of 
LDH, 2:1 and 3:1. They were loaded with the drug by co-precipitation and ion exchange. 
The samples were characterized by XRD, FTIR, Zetasizer analyzer, and the amount of 
drug loaded and released were determined by UV/Vis spectroscopy, and the results were 
compared to those of drug-LDH controls. Samples that have show successful 
intercalation of the drug in bi-layered arrangement are: co-precipitation samples using 
M
2+
/M
3+
 ratio of 3:1 (drug-LDH, G/GO-LDH), and ion-exchange samples, that don’t 
incorporate G/GO (drug-LDH), prepared using either M
2+
/M
3+
 ratios of 2:1or 3:1. Their 
loading amounts ranged from  25.4 to 51 % w/w, and they exhibited a sustained release 
over 24 hours with a release percentages, ranging from 2.1% (1.07 mg) up to 4.2 % (1.52 
mg). The other samples showed loading by surface adsorption on brucite-like layers of 
the LDH and the G or GO. They have drug loading amounts ranging, from 12.4 to 57.3 % 
w/w. This work demonstrated the potential of G/GO-Zn-Al LDH nanocomposites for 
sustained drug delivery. 
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Chapter 1. 
Introduction 
 
 
 
 
 
 
 
 
 
 
2 
 
1. Introduction 
 
1.1 Layered double hydroxides 
Layered double hydroxides (LDH) comprise a class of materials that can be either found 
as natural minerals in the soil, in sediments, as precipitants of saline water and hazardous 
waste sites, or could be synthetically prepared. They are used in a wide range of 
applications such as catalysis, filtration, drug or gene delivery, as exchangeable or 
absorbent materials, additives in polymer matrices or to create composites with other 
nanomaterials. These applications are based on the unique physical and chemical 
characteristics that LDHs possess such as high surface area, stability, large charge 
density, inertness, buffering effect, biocompatibility and great exchangeable capacity, in 
addition to the flexibility of controlling the surface layers and interlayer gallery content 
[1][2][3][4][5].  
1.1.1. Structure of LDH: 
LDHs are also known as mixed-metal-hydroxide anionic clays or hydrotalcite-like 
materials. Their structure is based on that of brucite [       ], which consists of 
Magnesium ions that are octahedrally surrounded by hydroxide ions. The octahedral units 
are connected end to end to form infinite layers and then these layers stack over each 
other to give a three dimensional structure. When a fraction of the divalent metal cations 
is substituted with trivalent cations, the hydroxide layers become positively charged. 
These positive layers are charge-balanced by the intercalation of anions in the interlayer 
gallery, which also contains water molecules, giving rise to Hydrotalcite, figure (1-1). 
Hydrotalcite was the first LDH discovered; it was introduced by Manasse in 1915, having 
a chemical formula of [           ]   .   ], and has been used as the reference 
term. After which Feitknecht in the late 1930s and 1940s introduced the term (Double 
sheet structure), describing a structure with intercalated hydroxide layers. And after the 
use of X-Ray diffraction for the study of minerals in the 1960’s, Allman and Taylor had 
well understood the exact structure of LDH [1][3][5][6]. 
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Fig 1-1. Schematic representation of hydrotalcite three dimensional structure [3]. 
 
Different compositions of LDH materials are prepared by changing the type of divalent 
and trivalent cations as well as the interlayer anions, but still maintaining a general 
formula of      
    
         
          .m  O, where  
  and    are the divalent 
and trivalent metal cations in the hydroxide layers respectively. Pure LDH structures exist 
at values of x in the range of 0.2 <   < 0.33, where x represents the metal ratio as    / 
(    +    ) or in the range of 2-4 when expressed as    /    ratio. When the   value 
is higher than 0.33, an impure form of LDH is formed due to repulsion between the 
increased positive charge density of the trivalent metal ions, allowing the inclusion of 
foreign ions. For   values less than 0.2, the lower positive charge density allows for less 
anionic inclusion, which would prevent the formation of the metal hydroxide and the 
structure collapses [1][3][6].  
  There are a wide variety of divalent and trivalent metal cations to choose from, with 
different ionic radii as shown in table (1-1) [3]. The metals are chosen according to the 
proper ionic radius that can form the hydroxide layers, therefore the most preferential 
radii are the ones close to those of Mg
2+
and Al
3+ 
ions as in brucite for divalent and 
trivalent metal cations respectively [1]. The order of stability is Mg < Mn < Co ≈ Ni < Zn 
for divalent metal cations, and Al < Fe for trivalent metal cations [1].   
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Table 1-1. Ionic radii of some common divalent and trivalent metal cations [3]. 
M2+ Radius 
(nm) 
M3+ Radius 
 (nm) 
Fe  0.061 Al 0.054 
Co  0.065 Co 0.055 
Ni  0.069 Fe 0.055 
Mg  0.072 Mn  0.058 
Cu  0.073  Ga  0.062 
Zn  0.074  Rh  0.067 
Mn  0.083  Ru  0.068 
Pd  0.086  Cr 0.069 
Ti  0.086  V 0.074 
Cd  0.095  In 0.080 
Ca  0.100  Y 0.090 
  La 0.103 
V4+ 0.058   
Ti4+ 0.061 Li+ 0.076 
Sn4+ 0.069 Na+ 0.102 
Zr4+ 0.072   
 
 
While     is the interlayer exchangeable anions, there is no limitation to the type of 
anions that could be incorporated within the interlayer galleries, as long as they 
compensate the positive charges of the hydroxide layers and generate purely prepared 
LDHs. Precautions are needed during preparation if using anions other than carbonates to 
prevent contamination with carbon dioxide from the aqueous solution or the surrounding 
environment. However, anions have different structures, radii (table 2-1), charges and 
charge densities that affect the basal spacing (interlayer distance + thickness of one 
brucite-like layer) or height of the LDH [3][6]. The charge density and bond strength are 
arranged in the following order: 
    
                     
      
       
        
       
  < 
   
   [3]. 
The weaker bonded anions could be easily exchangeable with other strongly bonded 
anions that are favored to be taken by the positively charged hydroxide layers, this 
characteristic provides the LDHs with their exchange capacity property. Finally m is the 
number of water molecules in the interlayer gallery filling the unoccupied spaces made 
by the anions [1][2][3]. 
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Table 1-2. Basal spacing values given by different intercalated anions in LDH [6]. 
Anions C’(A˚) 
OH- 7.55 
(CO3)2- 7.65 
F- 7.66 
Cl- 7.86 
Br- 7.95 
I- 8.16 
(NO3)- 8.79 
(SO4)2- 8.58 
(ClO4)- 9.20 
 
 
1.1.2. Preparation of LDH: 
Several synthetic techniques have been successfully used for the preparation of LDHs, 
and these include co-precipitation, classical ion- exchange and reconstruction techniques, 
with co-precipitation being the most simple, direct and commonly used among all 
techniques. There are other techniques such as sol-gel, salt oxide, hydrothermal and 
template methods and many others, but LDHs are not easily obtainable with these 
techniques and therefore not frequently used [3][4]. 
A- Co-precipitation 
In this preparation method, the synthesis conditions should reach supersaturation for the 
metal cations to precipitate, which takes place by controlling the pH at a value higher 
than or equal to the value at which the most soluble hydroxide is precipitated. Table (3-1) 
shows the pH values at which some metal cations reach supersaturation to create the 
hydroxide layers. The co-precipitation reaction could take place either at low 
supersaturation or high supersaturation conditions. In the former case, two solutions are 
added simultaneously together, one containing a mixture of divalent and trivalent metal 
salts with the ratio of choice and the other containing an alkali to maintain the desired pH, 
all into an aqueous solution containing the desired interlayer anions, and the pH is 
maintained by either manual control or by using an automated titration device. The anion 
that is to be intercalated should be of higher affinity to LDH and in excess amount to 
compete with the anions of the metal salts. Therefore, the most commonly used anions in 
metal salt precursors are nitrates and chlorides due to their weak affinity for LDHs and 
thus could be easily replaced with others. However, the desired anion could be readily 
included in the metal salt precursors, and in this case the alkali is added directly into a 
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solution of the metal salt precursors till the desired pH is reached. In case acarbonates are 
not the intercalating anions, precautions are to be taken by carrying the reaction under a 
nitrogen atmosphere, because of the high affinity of carbonates to LDHs. The advantages 
of the low supersaturation technique, are the capability to control the charge density of 
the hydroxide layers by controlling the pH, and the production of highly crystalline 
LDHs, that is for the increased rate of crystal growth rather than the rate of nucleation 
[1][3][4][6].  
As for the case of high supersaturation, the mixed metal salt solution is added to an 
alkaline solution containing the desired interlayer anion in excess. However, this 
technique has some disadvantages such as the generation of less crystalline and impure 
LDHs due to the increased rate of nucleation at the expense of crystal growth, because of 
the continuous alteration in the solution’s pH [1][3][4][6].  
 
Table 1-3. pH values of precipitation of some M
3+
 and M
2+
 hydroxides [1][6]. 
Cation  pH at 10-2 M  pH at 10-4 M  pH at which hydroxide 
re-dissolves  
Al3+ 3.9  8  9.0-12  
Cr3+ 5.0  9.5  12.5  
Cu2+ 5.0  6.5   
Zn2+ 6.5  8.0  14  
Ni2+ 7  8.5   
Fe2+ 7.5  9.0   
Co2+ 7.5  9.0   
Mn2+ 8.5  10   
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B- Ion exchange 
The ion exchange is another frequently used method when the co-precipitation technique 
is not applicable, such as when the divalent and trivalent metal cations or interlayer 
anions are unstable in alkaline media, or when the desired anions are difficult to 
intercalate by co-precipitation but rather favor direct anionic exchange. In this technique, 
the weakly held anions with low affinity to LDHs are exchangeable by the desired anions 
of higher affinity, depending mainly on the electrostatic interaction between the 
positively charged hosting sheets and the exchanging anions [1][3]. 
  The exchange takes place by stirring the LDH precursors with an excess of the desired 
anion in a solution [1][3]. The exchange follows one of the two following schemes:  
  LDH.A
m-
 + X
n-
   LDH.(X
n-
)m/n + A
m-
       scheme. 1 
or 
LDH.A
m-
 + X
n-  
+ mH
+  LDH.(Xn- )m/n + HmA     scheme. 2  
In the first scheme, the LDH precursors contain weakly bound anions such as nitrates, 
chlorides or perchlorates that are easily exchangeable with the anions to be intercalated. 
While the second scheme, which was firstly proposed by Bish, uses LDH precursors 
containing anions liable to acidic attack, such as carbonates and carboxylates [1]. 
There are some factors that should be considered for a successful ionic exchange; first, 
the affinity of the desired anion for the exchange, which increases with the increase of the 
ionic charges and the decrease of the ionic radii. Secondly, the solution medium for the 
exchange, the proper medium would allow the expansion of the LDH interlayer spacing 
for the exchange to take place. The aqueous medium favors the exchange by inorganic 
anions, while the organic medium favors the exchange by organic anions. The third factor 
is the pH of the medium, the low pH favors the exchange of less acidic anions with other 
more acidic anions from the solution, taking into consideration that at pH lower than 4 
the LDH would begin to dissolve. And at last the effect of the divalent and trivalent metal 
composition in the hydroxide layers expressed as M
2+
/ M
3+
  ratio, since it affect the 
charge density of the sheets and the hydration state, and hence affect the exchange with 
the incoming anions. Other factors such as temperature also has an influence on the 
exchange, since temperature favors the exchange, but too high temperature would distort 
the LDH structure [1][7]. 
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C- Reconstruction 
Reconstruction is another common preparation technique, also referred to as 
regeneration, restoration, rehydration, calcination-rehydration process or simply 
“structural memory effect”. In this technique the LDH is heated at a high temperature 
(calcined) to remove the interlayer anions, water molecules and hydroxyl groups, 
resulting in a mixed metal oxide. The calcined product is then rehydrated with water to 
regenerate the hydroxyl layers, and the interlayer anions and water molecules based on 
the memory effect of LDH. During regeneration, the anion of desire in the rehydrating 
water is incorporated into the interlayer gallery. The reconstruction process is greatly 
influenced by the pre-calcination temperature. For calcinations at temperatures less than 
or equal to 550 ºC, the reconstruction is complete within 24 hrs, while for calcinations at 
750 ºC, reconstruction requires 3 days to be complete. At 1000 ºC only partial 
reconstruction is observed. The advantages of this process is the ability to intercalate 
large guests that are difficult to intercalate by co-precipitation or ion-exchange and it 
ensures the absence of other competing anions such as the inorganic anions of metal salts. 
However, reconstruction is more complicated than co-precipitaion and ion exchange and 
produces less crystalline LDH [8]. 
 
1.1.3. Post treatment of prepared LDH samples: 
The synthesized LDHs are usually of poor crystallinity with disordered metal hydroxide 
layers. In the case of co-precipitation, the addition process of salt precursors and alkali is 
long enough for simultaneous nucleation and aging to take place, resulting in wide size 
distribution of crystals. Therefore, for an improved uniformity and crystallinity, the 
prepared precipitate is thermally treated at a temperature range of 273-373 K for few 
hours or days. The aging takes place via Ostwald ripening, by which large perfect 
crystallites grow and smaller ones disappear in the solution. Additionally, the produced 
precipitant should be washed thoroughly with deionized water to remove excess ions that 
may continue to react with the formed LDH [1][3][6]. 
 
1.1.4. Precautions during LDH preparation:  
As mentioned previously, LDHs have very high affinity for carbonate anions, and in case 
it is not the desired anion, the reaction should take place under nitrogen to exclude 
atmospheric carbon dioxide. Atmospheric oxygen should be excluded as well, in case the 
metal cations in the hydroxide layers are liable to oxidation such as divalent manganese, 
cobalt, iron and trivalent vanadium [1][3].   
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1.1.5. Applications of LDH:  
As mentioned previously, LDHs have been employed in various applications in present 
and others expected in the future. Their properties can be easily tailored to fit the 
specifications of any required application. These properties are relevant to their high 
surface area, high exchange capacity; to intercalate various organic and inorganic guests, 
high adsorption capacity, thermal stability and reconstruction at mild conditions via 
“memory effect” [5][9]. 
LDHs are commonly known for their use in catalysis, in the form of precursors, supports, 
or as actual catalysts. In addition to their use as adsorbents and exchange materials for 
water treatment to capture organic and inorganic wastes, specially that they are thermally 
stable and able to regenerate [10]. The chemical inertness, biocompatibility and null 
toxicity of LDHs had increased their use in the biological field [2][5]. LDHs are very 
excellent intracellular carriers, that can efficiently penetrate cell membranes and deliver 
high amounts of biological molecules into the target cells [11]. They can be used to create 
either a direct or sustained release dosage forms or as a storage compartments for drugs 
that are unstable under the influence of sunlight and high temperature. They can protect 
from gastric ulcers that are caused by some drugs such as anti-inflammatories, because of 
their barrier property that are similar to that of gastric mucosa, and their acid buffering 
effect. They enhance the water solubility of some non polar or slightly polar drugs, 
increasing their bioavailability. LDHs are not limited to drug delivery, but include 
negatively charged bio-molecules as well, such as single or double stranded DNA and 
small nucleotide molecules to expand their use in gene therapy, biosensing or even 
information storage in future approaches [5][9][10].  
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1.2 Graphene  
The first attempt to separate graphite layers was introduced by Boehm and co-workers in 
1962 via chemical reduction of graphite oxide. In 2004, the thinnest layer unit of 
graphite, namely graphene (G), was discovered by Geim and co-workers; they received a 
Noble prize in physics for this discovery. Since then, thin layers of G have grabbed the 
attention for their exceptional properties, including high electrical conductivity (    
S/cm), extraordinary mechanical properties with Young’s modulus, Poisson’s ratio and 
fracture strength of 1 TPa, 0.149 GPa and 130 GPa respectively, optical transparency, 
thermal conductivity (5000 Wm
-1 
k
-1
), high carrier mobility at room temperature (250,000 
cm
2
/V ) with charge carrier concentration of 1.4×1013 cm-2 and a huge surface area. 
These discoveries lead to exploring various means to incorporate G in applications such 
as in electronic and optoelectronic devices, as photoconductive materials in solar cells, in 
medical imaging, drug delivery, tissue engineering and as nano-fillers to improve the 
mechanical properties of some polymeric materials [11][12][13][15]. 
     
1.2.1. Structure of G:  
G is a building unit for other carbon-based structures, it is rolled into spheres, cylinders or 
stacked into layers to give fullerenes, nanotubes and graphite respectively 
[13][14][15][16]. However, the flat sheets of G have outstood these carbon allotropes for 
its unique properties and features [12].  
G is a planar sheet of one-atom thickness (~ 0.33nm). It is composed of    -bonded 
carbon atoms in two dimensional honeycomb Lattice. The unit cell of G lattice in real 
space comprises two carbon atoms belonging to two different interpenetrated sub-lattices, 
so that an atom from one sub-lattice is at the centre of the triangle defined by the other 
sub-lattice with a carbon-carbon inter-atomic length of 0.142 nm. This arrangement 
creates a triangular symmetry rather than a hexagonal one as shown in figure (1-2) 
[11][12][14]. Each carbon atom in the lattice has three    -hybridized orbitals in the 
same plane, providing the G sheets with its mechanical stability, while the unhybridized p 
orbital is perpendicular to the molecular plane. The free delocalized π electrons of the 
unhybridized p orbitals create a high electronic density above and below the 2D G plane, 
providing it with a highly reactive surface that can immobilize a large number of 
substances such as metals, drugs, bio-molecules, fluorescent probes and cells 
[13][15][17].  
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Fig 1-2. G layer consists of two interpenetrated triangular sub-lattice in two different colors, the atom of 
one sub-lattice (A) is located at the centre of the triangle defined by the other sub-lattice (B) [15]. 
 
Although G’s unique properties are associated to its single plane sheet, it is difficult to 
obtain G as a defect-free single layer due to its high surface area. This leads to the 
formation of irreversible agglomerates or even the restacking of multiple layers via Van 
der Waals interaction to form graphite again. Therefore, there are many chemical 
attempts for graphite exfoliation that focus on intercalation, chemical derivatization, 
thermal expansion, oxidation-reduction and use of surfactants, in order to maintain the 
inherent properties of G, and to employ it in most of the proposed applications. These 
chemical attempts produce a set of structures referred to as “G family nano-structures”, 
that include bilayer and multilayer G, graphene oxide (GO) and reduced graphene oxide 
(rGO), each one has its own surface chemistry, purity, defect density and compositions 
[11][12][13][14][18]. 
 
1.2.2. Graphene oxide: 
Surface functionalization of G sheets has been an efficient approach to prevent 
graphene’s agglomeration by introducing small molecules in between layers. Graphene 
oxide (GO) has been the most widely used form of exfoliated graphite [12][13]. It is a 
highly oxidized form of G, prepared by strong oxidation of graphite followed by 
sonication or other dispersion methods to provide monolayer materials, and can be further 
modified chemically to obtain G-based materials with suitable properties for a specific 
application [15][19][20]. 
As shown in figure (1-3), the surface of GO sheets is highly oxygenated bearing 
epoxides, alcoholic groups, ketone carbonyls and carboxylic groups [15]. The carboxylate 
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groups at the peripherals provide colloidal stability and pH-dependent negative surface 
charges, while epoxide (˗O˗) and hydroxyl (˗OH) groups are present on the basal plane, 
to allow for weak interactions such as hydrogen bonding and other surface reactions. The 
basal plane also contains free π electrons from the unmodified G areas, which are 
hydrophobic and can undergo π-π interactions. When the carbon atoms covalently bond 
to these oxygen containing groups, they partially convert sp
2 
conjugated system to sp
3
, 
weakening the van der Waals interactions between the sheets and increase the interlayer 
spacing of graphite from 0.35 nm to 0.65 nm to be ready for further exfoliation to single 
layers of GO. The oxidation and the harsh chemical treatments also impart topological 
defects, vacancies, cracks and edges in G lattice, increasing the chemical reactivity of the 
surface. The highly negative charged carboxylic and phenolic groups on the surface of 
GO render it hydrophilic due to their ionization in water to form uniform dispersions, 
which makes it very attractive for biological applications [13][14][15][18][21]. 
 
 
 
Fig 1-3. Structure of GO sheets [19]. 
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1.2.3. GO preparation: 
The most common method used nowadays for the preparation of GO is the Hummers 
method that was developed by Hummers and Offeman in 1958. The method is very 
simple, fast and productive. It exposes graphite to strong oxidizing agents to introduce 
oxygen containing functional groups on both sides of the single graphite sheets 
[12][14][18][22][23].  
A- Hummers method 
The most suitable starting material is the expanded graphite flakes with an average 
diameter of ~15 µm, because of its availability, cost effectiveness, and surface uniformity 
to provide a better oxidation and exfoliation performance [18][23].  
In this method, oxidation is achieved by adding concentrated sulfuric acid (H2SO4) into a 
mixture of graphite flakes and NaNO3, all in an ice bath (0ºC). This is followed by the 
addition of KMnO4 drop-wise to maintain the reaction temperature below 20ºC, and then 
warmed to 35ºC. At this temperature range, distilled water is slowly added producing an 
exotherm, and with the application of an external heat, temperature is maintained at 98ºC. 
The reaction is then terminated with the addition of water and 30% H2O2. The final 
mixture is purified by sifting, filtering and successive washing with distilled water, 30% 
HCl and ethanol, with the repetition of sifting, filtration, centrifugation and decantation 
after each wash. Finally it is dried under vacuum at room temperature for 24 hrs [18][24]. 
There are some disadvantages to the Hummers method, such as the release of toxic gases 
like NO2 and N2O4, and the difficulty to remove the oxidation residues (i.e. Na
+ 
and NO3
-
)
 
during purification. Moreover, it results in the production of GO with disrupted planes, 
because H2SO4 /HNO3 mixtures act as chemical “scissors” and “drills” for the G planes to 
facilitate the diffusion of the oxidants [18][22]. Hence, some modifications have been 
introduced to create a more eco-friendly oxidation method, such as ‘modified Hummers’. 
B- Modified Hummers method  
In the improved method, 9:1 mixture of concentrated H2SO4 / H3PO4 is added to a 
mixture of graphite and KMnO4, producing a slight exotherm of 35-40ºC. The NaNO3 is 
excluded in this method, which is the source of the toxic gases produced in the classic 
Hummers method, and is compensated for by increasing the amount of H2SO4 and 
KMnO4. The KMnO4 is a very strong oxidizing agent in acidic media; therefore, it 
improves the oxidation performance of H2SO4. The mixture is then heated to 50ºC and 
stirred for 12 hours. After cooling to room temperature, the reaction is terminated by 
pouring the mixture into ice containing 30% H2O2. Followed by purification with sifting, 
filtration, centrifugation and decantation, and successive washing with distilled water, 
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30% HCl and ethanol. For each wash, the mixture is sifted, filtered, centrifuged and 
decanted then finally dried under vacuum at room temperature for 24 hours [18][22].  
This improved method has some advantages over the unmodified Hummers, such as the 
low cost and oxidation temperature, it is less exothermic and produces no toxic gases, 
provides higher yield of GO with a less disrupted basal planes [18][24]. Therefore 
modified Hummers method is the most preferred approach for graphite oxidation. 
C- GO reduction 
GO has some limitations with respect to its mechanical, electrical and thermal properties; 
which are altered because of the functional groups that saturate the sp
2 
configuration. 
These groups disrupt the electronic structure, rendering the GO electrically insulating and 
reduce the charge-carrier concentration and mobility [12][13][14][21][25]. As for the 
mechanical properties, the Young’s modulus is reduced to 0.15-0.35 TPa. In order to 
restore these properties, GO undergoes reduction to decrease the oxygen content via 
thermal, chemical or UV treatments in presence of hydrazine or other reducing agents 
[13][18][21][25]. However, it will not be fully restored due to the additional defects, that 
are introduced during the reduction process [17]. 
 
1.2.4. Applications of G and GO: 
G has many unique properties that make it potentially promising in a large number of 
applications. The possibility of large scale production of GO and reduced GO has 
increased the opportunity for their use as reinforcements in polymer matrix composites. 
That is for their special mechanical, chemical, electrical and barrier properties, and aspect 
ratio [14][26][27]. These properties can contribute to exceptional features and high 
performance of the composite, such as gas and moisture barrier properties, 
electromagnetic shielding, electrical and thermal conductivity, increasing operating 
temperature level and improving compression strength [12][27].  
Nowadays, there is an increased attention towards solar cells that use G as an active 
medium or as an electrode material, or taking the advantage of  its chemical capabilities 
for energy storage and generation. The revolutionary in the electronics field has also 
utilized G as a planar channel material in high performance integrated circuits to produce 
touch screens, light emitting diodes and others [26][27]. 
However, G has recently expanded its range of applications to include biomedical ones 
such as in biosensors, tissue scaffolds, drug delivery, gene therapy or as antimicrobial 
agent. Such applications are made possible because of its relative properties such as large 
surface area, lateral dimensions, surface chemistry, purity and easy functionalization. It 
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can be a very promising ultrasensitive electrochemical or biological sensor 
[14][21][26][27]. Such sensing capability is made possible either via the charge transfer 
between the G monolayer and the adsorbed molecules, which is eventually translated into 
chemical responses, or via the functionalization of G with sensitive receptors for the 
detection of wide range of biological molecules (e.g. glucose, DNA, cholesterol and 
hemoglobin). In addition, it can serve as a single multi-dimensional measurement device. 
Moreover, in tissue engineering, the G’s unique high elasticity and flexibility have been 
very promising for its use as a reinforcement for biocompatible films, hydrogels and 
other types of scaffolds [19][26][27][28]. 
As for drug delivery, GO disperses well in water and has a good stability in physiological 
solutions, in addition to a large surface area, making it a good candidate as a drug 
delivery vehicle that can be given for systematic targeting or local administration 
[12][21][29]. Its large exposed surface area allows the high loading of a large number of 
molecules ranging from small drug molecules to big molecules such as antibiotics, DNA, 
proteins and genes with a good distribution and release profile. The hydrophobicity of G 
and the untreated edges of GO have increased the loading options to include insoluble 
drugs via π-π interactions and solving another challenge in drug delivery relevant to 
membrane barrier penetration [19][21][27]. Since the work here focuses on the 
biomedical applications, a great attention shall be given to its biological interactions, 
biocompatibility and the limitations for its uses. 
 
1.2.5. Biological interaction and toxicity of G and GO: 
 
A-  Biological interaction  
The biomolecular interaction is responsible for the determination of cellular uptake, renal 
clearance, blood-brain barrier permeability and other biological phenomena and 
therefore, understanding the properties relevant to the interactions is important to control 
G’s health and safety concerns [19][30].  
The mechanisms by which graphene based materials (GBMs) interact with the cell’s lipid 
bilayer, the layer that forms a barrier around all body cells, were introduced by Titov and 
coworkers. They conducted coarse-grained molecular dynamic (CGMD) simulation on G 
of different shapes, surface chemistries, different corners or edges, functionalizations and 
hydrophilic/hydrophobic property, in order to illustrate the dynamic process of G 
interaction with the lipid bilayer. In all cases the study agrees that G’s cellular uptake or 
penetration takes place via spontaneous localized piercing of the membrane by the most 
hydrophobic and sharpest edges of G, followed by spontaneous tilting of the G’s edges to 
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maximize its interaction to include the whole surface to achieve full penetration into the 
membrane interior as shown in figure (1-4). Therefore, the potential for G’s interaction to 
the lipid bilayers is due to its extended two-dimensional surface (5-10µm), 
hydrophobicity and sharp edges or protrusions, that are created during the fabrication and 
exfoliation processes. Whereas, GO is partially hydrophobic with rough edges and 
defects, that are produced during the harsh oxidation conditions, allowing it to interact as 
well with the lipid bilayers [19][30][31]. 
 
Fig 1-4. Coarse-grained molecular dynamics simulations of interactions between a lipid bilayer, (A-D) 
represent the small G sheet, and (E-H) represent interaction of larger multilayered G [30]. 
 
B-  Toxicity 
The effect of GBMs on living systems is very versatile and inconsistent, due to the 
different fabrication techniques, sizes, shapes, surface charges and functional groups. All 
of these properties need to be standardized in order to understand the exact mechanism of 
GBMs toxicity and impact on human health. The effect of GBMs on living cells is 
generally dependent on their concentration, exposure time and administration route. 
GBMs given intravenously (I.V) and via inhalation are the most studied: they are found 
to accumulate mainly in lung, liver and spleen, causing inflammation, pathological 
changes and apoptosis to the cells [20][32][33][34]. The inflammation is assumed to be 
due to the release of  the reactive oxygen species (ROS) as a defense response against the 
GBMs, that create a state of oxidative stress and damage the cells, but this mechanism is 
still unclear. However, the effect is greatly dependent on the given dose: in case of large 
doses equal or above 50 µg/ml they are found to show an obvious toxicity, while doses 
below 20 µg/ml fail to show any toxicity [14][32][33]. Size also plays an important role 
in evaluating the toxicity: sizes as small as 160± 90 nm induce high toxicity effects and 
cell apoptosis at concentrations equal to 200 µg/ml, while large sizes of 780± 410 nm 
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have less toxic effects causing only slight necrosis, respectively. As for medium sized 
GBMs of 430± 300 nm neither apoptosis nor necrosis is induced except for a decrease in 
cell viability at a dose of 200µg/ml. As for the studies made on GBMs that are 
administered orally are very limited. One of these studies detects the presence of large 
quantities of GBMs in the stomach and the intestines of mices within hours of ingestion, 
which were undetectable after one week, indicating their fast fecal excretion [14][20]. 
Another recent study has investigated the presence of G in the form of GO and other 
carbon nano-particles in the charred parts of roasted meat and in plant charcoal. This is 
used to prepare an approved medicine for infants’ known as “grip water” to treat 
stomachaches. Hardly any incidents of toxicity have been discovered [35].  
Current studies on GBMs toxicity, as claimed by researchers, are so far acceptable, and 
that the use of small doses may be safe. However, GBMs are more toxic in their free form 
and their modifications are still essential [34]. These modifications are to improve 
biocompatibility, solubility and reduce toxicity, and shall include all forms of G, even 
GO which is the most water soluble and biocompatible amongst all [20][31]. They can be 
modified with biocompatible, non-toxic materials either via covalent modifications such 
as atom doping and molecular interactions that further disrupt G’s surface structure, or 
non-covalent modifications such as Van der Waals, H-bonding or electrostatic 
interactions which produce a more flexible structure without the alteration of  their 
surface strucrure [17][32]. Examples of successful modifications are poly ethylene glycol 
(PEG) and dextran-functionalized G and GO that showed no significant toxicity or 
apoptosis to mice cells via I.V injection at a dose of 20 mg/kg or oral intake of 100 mg/kg 
of the mice’s weight [33] . 
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1.3 Bisphosphonates 
Bisphosphonates (BP) comprise a class of drugs that selectively prevent bone resorption 
(i.e. bone mass loss), and treat a number of bone diseases, such as menopausal 
osteoporosis, corticosteroid induced osteoporosis, Paget’s disease, malignant 
hypercalcemia and metastasis, and other osteogenic imperfections [36][37]. 
They are analogues of the inorganic pyrophosphate: a cellular metabolic byproduct that 
inhibits crystallization and prevents calcification in connective tissues, urinary tract and 
other extracellular fluids via its strong binding affinity to mineral crystals. This activity 
affects the minerals’ deposition inside the bone matrix and decreases its density. 
Therefore, to maintain the mineralization balance and allow for crystal growth, this action 
is reversed by alkaline phosphatase enzyme, which is present at the cellular linings; it 
hydrolyses the pyrophosphate before entering the bone and affecting the bone matrix. 
However, pyrophosphates do bind and promote the stabilization of formed crystals, and if 
allowed to saturate in the bone matrix, they may increase the crystal deposits and the 
bone density [38][39][40]. Therefore, non-hydrolyzable synthetic analogues such as the 
BP, have been developed for therapeutic purpose. As shown in figure (1-5), the chemical 
structure of BP comprises a carbon atom instead of oxygen which provides stability 
against hydrolysis by alkaline phosphatase, and it also allows for the presence of two 
more substituents/side groups than the phosphonate groups (R
1
 and R
2
). The binding 
strength and potency of BP can be easily tailored by varying R
1
 and R
2
 side groups 
respectively as shown in figure (1-6), which depicts their structure-activity relationship 
[36][37][38]. 
 
BP are classified into three generations based on the group at R
2
 position. The first 
generation lacks the nitrogen group such as clodronate and etidronate, the second 
generation has a primary nitrogen group such as alendronate and ibandronate, while the 
third generation contains a nitrogen group in a side chain cyclic ring as risedronate and 
zoledronate [41]. The potency of BP has been improving with each generation and 
nitrogen-containing bisphosphonates have proven to be the most potent generation and 
with the highest binding affinity to bone cells [42]. 
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Inorganic pyrophosphate Bisphosphonate 
 
Figure 1-5. The chemical structure of inorganic pyrophosphate and BP [37]. 
 
 
 
 
 
 
 
Figure 1-6. The structural-activity relationship of BP [36]. 
 
1.3.1. Nitrogen containing bisphosphonates: 
As mentioned previously, the nitrogen containing bisphosphonates (nBP) are the most 
potent, because the R
2
 side chain plays an important role in the interaction of  BP to the 
bone target and any slight change in the structure or conformation at R
2
 will dramatically 
affect the potency [39]. The nBPs’ pharmacological effect is not only relevant to their 
capability to bind and stabilize the mineral crystals, but also they interfere with relevant 
metabolic pathways due to their structural similarities  to active sites of some catalysts 
such as squalene; a biomedical intermediate for the synthesis of plant and animal sterols 
(ex. cholesterols). As shown in figure (1-7), they compete with squalene to interact with 
the farensyl diphosphate synthase (FPP) in the mevalonate pathway. They therefore 
inhibit the FPP induced isoprenylation (i.e. the addition of hydrophobic groups to 
proteins to facilitate attachment to cell membranes) of some GTPase. This controls a 
number of activities in the osteoclasts’ (bone cells that are responsible for resorbing bone 
minerals). The inhibition of farensyl diphosphate synthase is dose-dependent: at low 
When R1 is OH group. 
Binding to hydroxyapatite is 
enhanced. 
The P-C-P group is 
essential for biological 
activity. 
P-C-P acts as a “ bone 
hook” and is essential for 
binging to hydroxyapatite. 
The R2 side chain 
determines potency. 
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concentrations, the mineral dissolution process is inhibited, at relatively high 
concentrations osteoclast differentiation is inhibited, while at very high concentrations 
osteoclast apoptosis (cell death) takes place [42][43]. 
     
 
 
 
    
 
 
Fig 1-7. Pharmacological action of nBPs [42]. 
 
1.3.2. Biovailability of BP: 
BP are administered either intravenously (I.V.) or orally. Although oral BP are more 
convenient for patients than I.V., they have poor oral bioavailability (<1%) and cause 
gastrointestinal adverse effects such as oesophagitis and diarrhea, which will need dose 
adjustments to increase efficacy or lead to discontinuation because of incompliance. They 
have low oral bioavailability because they are highly polar, negatively charged at 
physiological pH of the intestine, which lead to unfavorable transport across the epithelial 
barriers. Their absorption is also affected by food intake and calcium supplements, and 
despite their high bioavailability at higher pH, they are taken after an overnight fast to 
prevent food interference [36][41][44][45]. 
 
 
 
 
Geranylgeranyl-PP 
Isoprenylation of GTPase  
nBPs 
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1.3.3. Pharmacokinetics of BP:  
The oral absorption of BP across the gastrointestinal tract takes place paracellularly (i.e. 
passage of molecules between tight junction of the cells), because of their low transport 
efficiency across the epithelial cells as mentioned previously. The absorbed dose is then 
distributed equally between the bone from which the drug is slowly released and the 
kidney for excretion. The amount of drug retained in the bone is partitioned between two 
drug pools: one at the bone resting surface where the drug is mobilized during the bone 
turnover into the bone fluid then into the blood, and the other partition is buried deep in 
the bone matrix. The drug mobilized into the blood is recyclable again into the bone and 
kidney till the amount is insufficient, while the drug embedded inside the bone remains 
active until resorption is induced by the newly formed osteoclasts, and that is when an 
additional dose has to be given to maintain the anti-resorptive efficacy. Although the 
usual administered doses shows a plateau for the resoprtion suppression, a higher or more 
frequent doses are recommended for higher efficiency [37][36][42]. 
 
1.3.4. Alendronate sodium: 
 
Alendronate sodium [(4-amino-1-hydroxybutylidene)bisphosphonic acid Monosodium 
Trihydrate] (figure 1-8), a water soluble nBP. It is the most efficient anti-resorptive agent 
and potent farensyl diphosphate inhibitor to-date, and it is the drug of choice in the 
treatment of  hypercalcemia in malignancy cases, postmenopausal osteoporosis and many 
other musculoskeletal disorders. Its clinical effect is based on increasing bone mineral 
density and strength, and reducing risk of fracture. Its mechanism of action, 
bioavailability and pharmacokinetics data are similar to the nBPs. It shows an oral 
bioavailability averaged 0.75%, with a linear oral absorption increase from 5 to 80 mg 
dose range. As a result of the addressed issues, many attempts have been made in order to 
develop new formulations for the alendronate sodium to enhance its bioavailability 
[37][45][46][47]. 
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Fig 1-8. The chemical structure of alendronate sodium in trihydrate form [37]. 
 
 
1.4. Statement of purpose  
The aim of this research work is to prepare a new hybrid nanocomposite of G/GO-LDH, 
and investigate its use as a drug delivery system for nitrogen containing bisphosphonate 
(alendronate sodium), this entails: 
 Preparation of a hybrid nanocomposite of Zn-Al LDH in its nitrate form with 
G/GO (G/GO-Zn-Al-NO3) using two different M
2+
/M
3+
 ratios of LDH (2:1 and 
3:1).  
 
 Loading the hybrids with the alendronate sodium with two different techniques: 
co-precipitation and ion-exchange. 
 
 
 Characterization of the samples by XRD, FTIR to determine successfully 
intercalated samples, and mechanism of loading. 
 
 Determination of the loaded drug amounts and the study of  the drug release from 
the hybrids by UV spectroscopy. 
 
 
 Compare the performance of the hybrid nanocomposite samples with LDH 
control with respect to drug loading and release.  
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2. Literature Review 
 
This chapter presents a review of the different approaches that have been developed to 
improve the delivery of pharmaceutically active molecules, with emphasis on those based 
on the utilization of LDH and GO as drug delivery platforms. A number of delivery 
systems that were investigated for improving the unfavorable physiochemical properties 
of alendronate sodium will also be represented.  
2.1. LDH intercalated systems  
2.1.1. Non Steroidal Anti-Inflammatory Drugs (NSAIDS) intercalated 
LDHs: 
 
 NSAIDS anti-inflammatory drugs, are commonly used in cases of arthritic rheumatism, 
osteoarthritis, muscle pain, metastatic bone pain, migraines and many other medical 
cases. However, they are associated with low solubility, poor delivery control and 
administration adverse effects; such as gastric and duodenal ulcers. Intercalation of 
NSAIDS into the LDH matrix, has improved their water solubility and release rate. The 
LDH has provided an additional advantage by introducing a buffering effect to protect 
against the ulceration damages [48][49]. 
 
The anti-inflammatory fenbufen was intercalated by Evan et al. into Mg/Al and Li/Al 
LDHs in their nitrate form by co-precipitation under pH 8 [50]. The drug was intercalated 
successfully as monolayers in the LDH interlayer gallery, and upon increasing the pH 
from 8 to 12, the amount of intercalated fenbufen was increased, indicating the possible 
formation of bilayers as suggested by the increased gallery spacing. The Mg/Al LDH 
system proved to be more effective as a controlled release system, giving a gradual 
release over time compared to Li/Al LDH [48][50].  
 
Del Arco et al. intercalated fenbufen into Mg/Al LDH and Mg/Al/Fe LDH systems, by 
co-precipitation and ion exchange, using the chloride LDH form, and by reconstruction 
using the LDH nitrate form [51]. The intercalation was successful in case of Mg/Al LDH 
by the three preparation techniques, but fenbufen was only intercalated by co-
precipitation and ion exchange in case of Mg/Al/Fe LDH. This was because Fe inhibited 
the intercalation after the LDH reconstruction. The total drug release was more restrained 
in case of the Mg/Al/Fe LDH system (only 59% in 1 h), due to the strong interaction 
between the drug and the hydroxide layers, while the release from the Mg/Al system was 
complete in only 2 h [48][51]. The study was extended by coating the LDH-drug hybrid 
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with an enteric coat such as Eudragit® S100, and uniform and smooth microspheres were 
produced, showing high stability at low pH (<7) [51]. The same results were found by 
Evans et al., who proved that the strong interaction between the Eudragit® S100 and the 
LDH further restrained the drug release [48]. 
   
Naproxen is another anti-inflammatory that was successfully intercalated by Duan et al. 
into Mg/Al LDH in its nitrate form by ion exchange under pH 8. The study proved the 
thermal stability of the system. This was acquired by the naproxen upon intercalation 
compared to the free form, suggesting an additional advantage of the LDH as a promising 
delivery system [48][52].  
Berber et al. also intercalated the naproxen into Mg/Al LDH by co-precipitation and 
reconstruction with the LDH chloride form at pH 8. The drug was intercalated more 
successfully by co-precipitation than by reconstruction, and the drug dissolution in the 
acidic media was improved compared to the free drug. The same approach was followed 
by Del arco et al. using the three preparation techniques. The intercalated amount of 
naproxen was almost the same in case of co-precipitation (44.2%) and ion exchange 
(46.5%), but very low in case of reconstruction (38.4%) due to possible contamination 
with interlayer carbonates. The drug dissolution was improved in acidic medium, 
compared to the free drug and the release was found to be more controlled [48][53][54].  
 
The Zn/Al LDH system was used by Hou and Jin to intercalate naproxen by the ion 
exchange method [48][55]. The intercalation of the drug was successful, and the 
interlayer distance increased to 18.78 Å, which is greater than the drug’s height (12.20 
Å), indicating the arrangement of the drug as overlapped bilayers and high drug loading. 
They studied the effect of some variables such as the structural charge density, 
composition and the pH on the amount of the drug loaded, in addition to the effect of 
using LDH on the drug release rate. The increase of the charge density increased the 
amount of the drug loaded because of the interaction between the positively charged LDH 
layers and the negatively charged naproxen. On the other hand, the increase of pH from 6 
to 11 caused a linear decrease in the amount of loaded drug, because the charge density 
decreased with the increase of pH [55]. The composition of the interlayer anions were 
also of significance, both chlorides and carbonates were investigated as the interlayer 
anions. It was found that the intercalation was more successful in the case of chlorides 
because it was more readily exchanged with drug. Finally, the Zn/Al LDH was proved 
efficienct as a controlled release system when compared to free naproxen [48][55].  
   
Ambrogi et al. successfully intercalated the anti-inflammatory ibuprofen and diclofenac 
in Mg/Al LDH with its chloride form by ion exchange, suggesting their arrangement as 
monolayers and bilayers respectively, which was indicated by the increased value of the 
interlayer space compared to the drugs’ molecules sizes. They investigated the LDH 
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capability to control the release of the drug. It was found that the release of ibuprofen and 
diclofenac in the phosphate buffer solution took place over 24 hours, the slow release 
being attributed to the rate of phosphate anions’ diffusion onto the interlayer gallery and 
their exchange with the intercalated drug [48][56][57]. They extended their work to 
prepare enteric-coated microparticles of diclofenac-LDH to protect against gastric attack. 
The microparticles were prepared by an oil-in-oil solvent evaporation method, using the 
intercalated LDH and a mixture of Eudragit® S100 and Eudragit® L100 polymers with a 
ratio of 1:5 or 1:10 w/w. The microparticles combined between the two release strategies: 
the pH-dependent polymer solubility and the ion exchange release mechanism of the 
LDH [48][58]. 
   
Perioli et al. used the Zn/AL LDH with its bromide form to intercalate diclofenac drug, 
using the ion exchange mechanism. After the successful intercalation, they studied the 
effect of the particle size on the drug release [48][59]. The release of the drug from the 
nano-sized and micro-sized particles were compared, showing no difference of their 
release and indicating that the ion exchange was the rate-limiting step [59].  
 
Rives et al. intercalated diclofenac and ketoprofen into Zn/Al and Mg/Al LDH systems 
with its nitrate form by co-precipitation. The increased height of the interlayer gallery in 
case of the two drugs is 23 Å, and when compared to the drugs’ molecular sizes, 
suggested their arrangement as tilted bilayers. The strong interactions between the drug 
and the LDH layers proved to be another indication to the thermal stability of the 
intercalated drug at very high temperature compared to its free form [48][60]. 
 
2.1.2. GO and drug intercalated LDHs: 
 
The first attempt for the use of GO/LDH hybrid in biological systems was reported by 
Zhang et al. (2012). Their objective was to prepare antibiotic-intercalated LDH-GO 
composite by a simple solvent evaporation method. The delivery system combined the 
antibacterial activity of GO and its ability to incorporate a variety of drugs, and the 
LDH’s ability to store the drug and control its release. A Mg-Al LDH, with nitrate as the 
interlayer anion, was used as a precursor into which the benzyl penicillin (BP) antibiotic 
was intercalated by ion exchange. The as-prepared BP-LDH was then mixed with GO 
under vigorous shaking and ultra-sonication, relying on the formation of electrostatic 
interactions between GO and LDH, followed by washing and drying completely. The 
release of the drug from the hybrid was much slower than that of free LDH and could be 
adjusted by controlling the GO/BP-LDH ratio: the lower the ratio of GO/BP-LDH the 
higher the time of the release. As for the biological activity, the hybrid was observed to 
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show a synergistic antibacterial effect, due to the combined antibacterial activity of the 
BP and GO, which also increased with the decrease of the GO/BP-LDH [61].     
     
2.2. GO based delivery systems 
2.2.1. Delivery of anticancer drugs: 
The use of chemotherapeutic drugs to treat cancer is challenged by their non-selective 
cytotoxicity and hydrophobicity, which has imposed the need to develop efficient 
targeted drug delivery systems [47]. GO serves as a promising drug delivery vehicle as its 
high surface area is available for variable dynamic interactions with different bio-
molecules and drugs [62][63]. 
In 2008, Dai et al. pioneered the development of a modified GO for biological 
applications. Six-armed polyethylene glycolamine polymer (PEG) was  grafted onto the 
surface of GO to impart biocompatibility and aqueous stability without aggregation. The 
GO-PEG hybrid was then loaded with the anti-cancer doxorubicin (DOX) via π-π 
stacking and hydrogen bonding at high loading capacity. The PEG shell gave the drug 
high stability during blood circulation till it reached the tumor, where the drug was 
released due to its increased solubility in acidic media [63][64].The tumor-targeting of 
the GO-PEG-DOX system was based on the fact that the tumor microenvironment is 
acidic (pH 5.5). On the other hand, PEG acts as a diffusion barrier that can adversely 
delay the release of the drug. In 2012, Shi et al. solved this issue by developing a GO 
delivery system with a redox-responsive detachable PEG shell. A cytamine modified 
PEG (PEG-SS-NH2) was grafted onto the surface of GO via the disulphide linkage 
(NGO-SS-mPEG) [65]. The encapsulated drug was rapidly released from the formulation 
by selective degradation of the disulphide linkage when exposed to the relevant levels of 
reductive glutathione (GSH) at the tumor site, imparting higher intracellular 
concentration of the drug, and consequently increasing the inhibition of cell proliferation 
[63][65]. Later, Ji et al. developed a simpler method for the preparation of the same 
hybrid system. The PEG-SH was conjugated to GO-SH via disulphide linkage by using 
only air as an oxidizing agent. Moreover, they conducted a comparative study of the 
intracellular drug release and cytotoxicity between NGO-SS-PEG/DOX and NGO-
PEG/DOX, to prove that the rapid release of the drug from the NGO-SS-PEG conjugate 
with a detachable PEG shell was very specific to the tumor’s relevant GSH levels, 
therefore, it showed higher therapeutic effect than that of NGO-PEG. They also reported 
GO-SS-PEG/DOX as an efficient chemo-photothermal therapy, by demonstrating the 
effect of photothermia on the release of DOX from both hybrid formulations. The results 
showed an accelerated release of DOX in the case of NGO-SS-PEG/DOX by heat and 
hence, the disulphide linkage breakdown [66]. Liu et al., created the 3D version of the 
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redox-responsive PEGylated G nanocarrier (GON-Cy-ALG-PEG) for the delivery of the 
anti-cancer DOX. It was prepared by conjugating cytamine modified PEGylated alginate 
brush to GO, via disulphide linkage. The system succeeded to achieve a targeted delivery 
of DOX to the tumor site, showing very high cellular uptake, with no obvious toxicity up 
to 200µg/ml. However, it was recently reported that the disulphide linkage of the 
detachable PEG shell was also susceptible to degradation by enzymes, which led 
researchers to take alternative strategies [63].  
Gan et al. reported a novel nanocarrier, by covalent functionalization of GO with chitosan 
(CS). CS is a natural polysaccharide, which is biocompatible and serves as a low 
immunogenic drug carrier. Its solubility is affected by pH changes: it is poorly dispersible 
in alkaline pH, but forms homogenous dispersions in acidic pH, which was relevant to the 
release mechanism of the drug from the GO-CS carrier as a response to the acidic 
environment of the tumor [63][67]. The GO-CS was demonstrated as a drug carrier for 
water-insoluble anti-cancer camptothecin, exhibiting a very high aqueous stability and a 
loading capacity of 20 % (w/w), which was twice that reported in the case of PEGylated 
GO. The carrier also proved to be non-toxic to healthy cells and with remarkable 
cytotoxicity to tumor cells [67]. To further increase the targeting property of the GO-CS 
carrier, Yang et al. incorporated folic acid (FA) to the chitosan carrier (FA-CO), as a 
targeting molecule for tumor cells with over-expressed folate receptors on their surface. 
The cellular uptake of DOX was very high when compared to GO-CS [68]. Tang et al. 
prepared the same hybrid, but in a one-step preparation method. The composite was 
prepared by combining GO, folic acid and trimethychitosan (TMC) in a single system to 
prepare a modified FA with TMC (FTMC), which spontaneously conjugated with GO via 
self assembly [69].  
FA functionalized GO was prepared by Lin at al. by a one-pot synthetic technique, taking 
the advantage of the self-polymerization of Dopamine (DA). The anti-cancer DOX and 
the targeting molecule (FA) were immobilized simultaneously during the polymerization 
on the GO surface, the polymerization was controlled by only pH adjustment and 
excluding any chemicals or organic solvents; hence this represented a simple, low cost 
and eco-friendly approach. A 100% loading capacity of the active DOX was achieved, 
and was released in a sustained manner depending on the dissociation of the H-bonds 
between GO and DOX [47].  
Wu et al. functionalized GO with a different targeting molecule: hyaluronic acid (HA), 
which is a natural polysaccharide that exists in cellular matrix, connective tissues and 
body fluids. The hybrid (GO-HA) selectively targeted the delivery of DOX to tumor cells 
via receptor-mediated endocytosis through receptors such as cluster determinant 44 
(CD44) and receptors for hyaluronic-mediated motility, which are highly expressed in 
tumor tissues. The delivery efficiency was proved by the significant tumor suppression 
after intravenous injection of mice by 40% and with no significant toxicity or 
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inflammatory reactions [70]. Song et al. prepared the same hybrid, but instead of loading 
the DOX onto the prepared GO-HA as in the previous work, the GO was first loaded with 
DOX via π-π stacking and H-bonding, and then conjugated to HA via H-bonding, 
achieving a loading efficiency of 42.9% and an entrapment efficiency of 69.5% [62]. 
 
2.2.2. Delivery of active proteins: 
 
The role of proteins in regulating gene expressions and cellular signals pathways, justifies 
their potential in cancer therapy. Protein-based therapy has many advantages over the 
conventional chemotherapy, such as less side effects and less immunogenicity. However, 
the poor cellular uptake and enzymatic hydrolysis have restricted the use of active 
proteins in biotherapy. Zhang et al. demonstrated the use of GO functionalized with PEG 
(GO-PEG), that was previously developed by Dai et al., as a vector for the delivery of 
active proteins; GO protected the protein from enzymatic hydrolysis and retained its 
activity till it reached the cells. In this study the GO-PEG was loaded with bovine serum 
protein (BSA) as a model protein via physisorption to investigate the loading and release 
behavior. The loading capacity was very high, which was attributed to the high loading 
surface of GO, with a gradual release of the protein in phosphate buffer solution. As for 
the stability of the proteins, the GO-PEG/protein complex was investigated versus free 
protein in presence of digesting enzymes. The complex showed an intact protein, owing 
to the steric hindrance created by the GO that prevented the digesting enzymes to reach 
the protein [71].   
 
A different strategy for the delivery of proteins was established by Park et al. A pH-
sensitive poly(acrylic acid) (PAA) polymer was grafted to GO surface by in situ radical 
polymerization to create GO-PAA for the oral delivery of protein in their active form 
without being degraded. The PAA is a weak anionic polyelectrolyte polymer that is 
greatly dependant on the surrounding pH: the polymer was protonated at low pH of the 
upper GIT, causing its shrinkage and protein retention, while at high pH of the intestine it 
was deprotonated, and swollen by the electrostatic repulsion between the chains, allowing 
the protein to be released. This complex provided both high loading capacity and 
protection of the protein via the pH-dependant behavior of the polymer [72]. 
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2.3. Alendronate sodium delivery systems 
 
A few approaches were adopted to overcome the unfavorable physiochemical properties 
of alendronate sodium, such as poor membrane permeability and esophageal irritation. 
One of such approaches was based on the use of liposomal nanoparticles as a delivery 
system. The liposome improves the membrane adhesion, permeability and absorption of 
hydrophilic drugs, but due to its instability against chemical and enzymatic degradation in 
the intestine, Han et al. coated its surface with chitosan. The positive charges of chitosan 
created a shield around the liposome preventing acids or enzymes from reaching the 
liposome’s surface, and providing an additional advantage by decreasing the drug’s 
leakage and minimizing contact with the esophagus. The chitosan also interacted with the 
negatively charged mucus layer of the intestinal epithelial cells, increasing its resident 
time in the intestine and hence its oral absorption and bioavailability [73]. 
 
Enteric coating of the liposomes is another technology that protects against gastric and 
enzymatic attack. Hosny et al. prepared the enteric coated liposomes: first the liposomes 
were prepared from a mixture of phosphatidylcholin, cholesterol and lecithin, with the 
mass ratio of 4:3:1 to achieve the highest encapsulation efficiency (49.39%), integrity and 
stability, and then the poly(meth)acrylate (Eudragit
®
 S100) was added to impart enteric 
coating. To further enhance the liposomal stability, a negatively or positively-charged 
enhancer such as stearylamine (SA) and dicetyl phosphate (DO) respectively, were mixed 
with the liposomal lipid components. The positively charged enhancer (SA) was found to 
increase the encapsulation efficiency due to the attraction force between its positive 
charges and the negatively charged alendronate sodium. In the case of the negatively 
charged enhancer, there was a repulsion force with the negatively charged drug, however, 
it had an attraction force with the Eudragit positive charges, improving its coating 
efficiency and showing more resistance to the gastric and enzymatic attacks. Therefore, 
the negatively-charged enteric-coated liposomes were shown to have optimum features 
allowing for high bioavailability and protection against esophageal irritation [74]. 
 
Polymeric micro particles were also among the systems used to overcome the 
gastrointestinal adverse effects associated with alendronate sodium oral intake. Cruz et al. 
prepared polymeric micro-articles by spray drying of alendronate sodium with 
poly(meth) acrylate (Eudragit
®
 S100) and another with a blend of Eudragit
®
 S100/methyl 
cellulose, with mean diameter below 17 µm. Both formulations of micro particles had 
high encapsulation efficiency, and showed a slow release of the drug, with more delay in 
presence of methylcellulose. As a consequence of delayed release, the gastrointestinal 
injuries were almost diminished [46].  
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The potentials of solid lipid nanoparticles (SLNs) such as high drug loading, drug 
stability and low toxicity have recently increased their use as a drug delivery system for 
different administration routes. The SLNs have a lipid matrix that can incorporate 
hydrophobic as well as hydrophilic drugs, and alendronate sodium were demonstrated by 
Hadi et al. as the drug model. The alendronate sodium loaded SLNs were prepared by 
simple hot homogenization technique: emulsification followed by solidification without 
the use of organic solvents. Very high encapsulation efficiency (70-85%) was achieved, 
and a sustained release of the drug was also achieved owing to the solid matrix of the 
nanoparticles [75].  
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3. Theoretical Background 
 
This chapter presents the theories behind the characterization and the analytical 
techniques used in this work, and which includes X-ray diffraction (XRD), Scanning 
electron microscopes (SEM), Ultraviolet/Visible (UV/Vis), Fourier Transform Infrared 
(FTIR) spectroscopy and Zetasizer analyzer.   
 
3.1. X-ray diffraction (XRD)   
 
X-rays were discovered by the physicist Wilhelm Röntgen in 1895, followed by Gordon 
Darwin in 1912 who established the dynamic theory of X-ray scattering by a crystal 
lattice. X-rays are electromagnetic radiations that lie in between gamma and ultraviolet 
radiations in the electromagnetic spectrum. They have a wavelength range of 0.1-100 Å, 
which is almost in the same range as that of the size of atoms, making them eligible for 
studying and characterizing materials at the atomic level. XRD is used to obtain structural 
information of crystalline samples such as unit cell lattice parameters, crystal phase 
composition, degree of crystallinity, residual stress, texture and orientation [76][77][78]. 
To have a complete understanding of the technique, some important principles are to be 
discussed first.  
 
 
 
3.1.1. Principle of XRD: 
          A- X-ray generation 
X-rays are electromagnetic radiations that occur whenever an electric charge accelerate or 
decelerate. The wavelength used for the crystallographic detection is 0.5-2.5 Å, which is 
associated with very high energy that enables the X-rays to penetrate through the sample 
and detect the smallest inter-atomic distances, and that what makes it a very powerful 
detection tool. Figure (3-1) is a Bohr model of an atom to explain the generation of X-
rays. The nucleus is surrounded by shells hosting electrons, and when a beam of electrons 
hits the target material at a very high speed, an electron in an inner shell (K-shell for 
example) is ejected, leaving behind a positive hole which is then filled by an higher 
energy electron (from the  L or M shells for example). This electronic transition produces 
two types of X-rays known as: Kα X-rays which are of very high intensity, and Kβ X-rays 
34 
 
which are of lower intensity. Kα and Kβ reflect the transitions of electrons from L- to K-
shell and from M- to K-shell respectively, and are very characteristic of the atomic 
structure of the target material [77][79]. Table (3-1) shows the commonly used target 
materials and their wavelengths. 
 
 
 
 
Fig 3-1. Diagram of X- ray generation [70]. 
 
Table 3-1. Target materials used in X-ray tubes and their characteristic wavelengths [79]. 
Element Wavelength (Å) 
Mo 0.7107 
Cu 1.5418 
Co 1.7902 
Fe 1.9373 
Cr 2.2909 
 
 
B- Crystals 
 
Solid matter is classified into amorphous and crystalline solids. Amorphous solids lack 
order in the arrangement of their units, which can be atoms, ions or molecules. On the 
other hand, crystalline solids, which represents 95% of all solid materials, have their units 
arranged in periodic arrays with long-range order. The unit cell is the smallest volume 
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element, when repeated in three dimensions, defines the crystal structure. The unit cell is 
described by three main axes: a, b and c where α, β and γ represent the angles in between, 
as shown in figure (3-2). The variation in these parameters gives rise to seven different 
shapes of unit cells as in table (3-2) [76][78][80]. 
 
 
Fig 3-2. Three dimensional unit cell [76]. 
 
 Table 3-2. Different shapes of unit cells and their possible axis systems [80]. 
 
Crystal system Axis system 
Cubic  a=b=c, α=β=γ=90º 
Tetragonal  a=b≠c, α=β=γ=90 º 
Hexagonal  a=b≠c, α=β=90 º γ=120 º 
Rhombohedral  a=b=c, α=β=γ≠90 º 
Orthorhombic  a≠b≠c, α=β=γ=90 º 
Monoclinic  a≠b≠c, α=γ=90 º β≠90 º 
Triclinic  a≠b≠c, α≠β≠γ≠90 º 
 
 
  When parallel planes of atoms are intersecting the unit cell, they define orientations and 
inter-planar distances through the Miller indices (hkl), which represent the reciprocals of 
the intersections of each of the three axes in the unit cell. For example, in figure (3-3), 
planes that cut the x-axis at a/2, b-axis at b and c-axis at c/3, are described by the Miller 
indices (213) [79][80]. 
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Fig 3-3. Parallel planes of atoms intersecting the unit cell [77]. 
 
- X- ray scattering:   
The units in a crystal are arranged in long-range periodic arrays, and upon hitting a 
crystalline matter X-rays cause the electrons surrounding each atom in the periodic arrays 
to oscillate, scattering the radiation. This scattered radiation is in phase, and constructive 
interference is obtained, resulting in waves of high intensity [79][76][80][81]. These 
diffraction patterns give information about the units arrangement within a crystal, helping 
elucidate the crystal structure and presenting a fingerprint for each crystalline material 
[78][81]. 
- Bragg’s law: 
 
Constructive interference of diffracted rays occurs when meeting certain geometric 
conditions. This is expressed by Bragg’s law. The relationship between the diffraction 
angles, X-ray wavelength and inter-planar space is represented as follows in equation (1) 
[78]: 
                                     
                    eq.1 
where, n is the order of reflection (n=1), λ is the wavelength of the X-ray, d is the 
distance  between parallel planes, and θ is the angle of incident ( which is equal to angle 
of reflection) [78]. 
The application of Bragg’s law is schematically presented in Figure (3-4). The incident 
and reflected rays form an angle (θ) with the parallel planes separated  by a spacing “d”. 
for the reflected rays to be in phase, the length difference between their paths must be a 
multiple of their wavelength [76][78][79]. 
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Fig 3-4. X-ray reflection from two parallel planes [81]. 
 
 
3.1.2. Instrumentation of XRD: 
  
In X-ray powder diffraction, the sample should be grounded well into a fine and smooth 
powder to have a homogenous and randomly oriented sample crystals, to obtain a random 
distribution of all the possible planes that contribute to the production of constructive 
reflections of the crystal structure. Large non-randomly oriented crystal sample will give 
rise to variation of peak intensities [78][79][80][81]. 
 
The typical geometry used for powder XRD is the  Bragg-Brentano one, presented in 
Figure (3-5). The X-ray tube is stationary, the sample rotates at an angle theta (θ) from 
the X-ray tube, while the detector rotates at an angle 2-theta (2θ) from the X-ray tube, 
detecting the diffracted beams and recording the high intensity of constructive 
interference when it occurs as per Bragg’s law (eq.1). When X-ray intensity is plotted 
against the angle 2θ, as shown in Figure (3-6), the high intensity signals are those where 
Bragg’s law is met, and which correspond to X-rays constructively reflected from planes 
with different “d” values. The dimensions of the unit cell can also be determined 
[78][79][80]. 
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Fig 3-5. The Bragg-Brentano geometry [76]. 
  
 
 
 
Fig 3-6. An example of XRD chart [79]. 
 
3.2. Ultraviolet/Visible (UV/Vis) spectroscopy 
3.2.1. Principles of UV/Vis spectroscopy: 
 
The absorption of electromagnetic radiation in the UV or Vis range causes an energy 
change (ΔE) in the valence electrons of a molecule or an atom, leading to electronic 
transitions when ΔE of the transition corresponds to the energy of the incoming radiation. 
In this case, the incident radiation of this energy value will be absorbed by the sample, 
and the remaining radiation will be transmitted [82][83][86].  
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Absorbance is the measure of this absorbed radiation and is directly proportional to the 
amount of absorbing species (atoms, ions or molecules) in a sample. This relation is 
expressed by the Beer-Lambert as follows in equation (2):  
 
 = ε × c×           eq.2 
 
Where (ε) is the molar absorption coefficient, a material specific constant, (c) is the 
concentration of the absorbing species in the sample and (d) is the path length of the 
radiation through the sample [82][83][86]. This relation then allows the determination of 
unknown concentrations using calibration curves constructed using known 
concentrations. Beer-Lambert law (eq.2) however is only applicable in low concentration 
ranges, and at higher concentrations, the linearity between Absorbance and concentration 
no longer holds. 
 
3.2.2. Instrumentation of UV/Vis spectroscopy: 
There are two types of UV/Vis spectrophotometers: single-beam and double-beam 
spectrophotometers. The simple single-beam set up as shown in figure (3-7) has a single 
optical path from the source to the detector, using a fixed-wavelength monochromator. It 
requires calibration every time before measuring the sample. The advantage of this set up 
is that it is relatively inexpensive and easily transported, but on the other hand the 
recalibration process is time-consuming and the spectrophotometer is less accurate than 
the double-beam spectrophotometer [83]. It is therefore useful for measurements at a 
particular value of wavelength. 
 
 
 
Fig 3-7. Schematic diagram of single-beam spectrophotometer setup [83]. 
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As for the double-beam spectrophotometer in figure (3-8), the setup comprises the 
radiation source, followed by a monochromator to select the required wavelength falling 
onto the sample. The beam is split into two equal parts by a half mirror to simultaneously 
pass through a blank and the sample. The detector collects both beams, determining the 
sample Absorbance at this particular wavelength. When the Absorbance is plotted against 
wavelength values as in figure (3-9), the Absorbance spectrum of the sample is obtained 
where the wavelength of the highest Absorbance represents λ max, which is characteristic 
for each substance. The double-beam setup is more expensive but more versatile and 
accurate than the single-beam setup [82][83][86]. 
 
Fig 3-8. Schematic diagram of double-beam spectrophotometer setup [82]. 
 
Fig 3-9. An example of a UV spectrum [86]. 
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3.3. Fourier transform Infrared (FTIR) spectroscopy 
 
3.3.1. Principles of FTIR:  
FTIR spectroscopy gives important information about the sample’s identity and the 
number of components in a sample mixture [87]. For a sample to absorb IR radiation, the 
radiation must induce molecular vibration associated with a change in the dipole moment 
of a molecule in the sample. When the energy of the molecular vibration is equal to that 
of the IR radiation, absorption takes place. A general model in figure (3-10) represents 
the molecular system as atoms connected to each other by a spring-like bonds that expand 
and contract as a response to the vibrational frequencies [90][91]. 
 
 
Equilibrium  
bond length 
Stretched  Compressed 
 
Fig 3-10. Changes in the dipole moments of a diatomic molecule [91]. 
 
The atoms are continuously moving relative to each other around their central atom in 
two common vibrational modes: stretching and bending. In the stretching mode, a change 
in the bond length takes place. Stretching can be classified into symmetric (in-phase 
stretching) and asymmetric (out-of-phase stretching) modes (figure 3-11.a). In bending 
modes, a change in the angles between the atoms occurs. Bending is classified into 
rocking, scissoring, wagging and twisting (figure 3-11.b). Since the change of the 
molecular dipole moment is a must for IR-radiation absorption to take place, the greater 
the change, the higher is the absorption intensity. The stretching mode represents the 
most detectable and useful peaks in the IR spectrum, because stretching the bonds 
between two atoms of different electronegativities greatly changes the dipole moment 
[90][91][92].    
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(a) 
 
(b) 
Fig 3-11. Stretching (a), and bending vibration (b) modes [93]. 
The frequency of the vibrational modes can be calculated mathematically when the 
stretching vibration is approximated by Hooke’s law, that is derived from the simple 
harmonic oscillator model. The frequency (υ) of the vibration is related to the force 
constant (   of the spring and the reduced masses of the atoms (   as follows in equation 
(3) [88][89][90]:  
υ = 
 
  
 
k
 
             eq.3                            
The value of the reduced masses is calculated as follows from equation (4) where 1 and  
 2 are the masses of involved atoms [88][89][90]: 
μ = 1 2 /  1 + 2)         eq.4 
And to have a direct use of the wavenumber values of the vibrational frequencies, the 
first equation is modified as follows in equation (5): 
ῡ = 
 
   
 
k
 
            eq.5          
where ῡ is the wavenumber and c is the speed of light [88][89][90].   
When applied to a molecule in a sample this model leads to different vibrational modes of 
the different functional groups constituting the molecule. This leads to the absorption of 
the radiation of energies equal to the energies of each of these vibrational modes, leading 
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to a spectrum for the sample, with absorption bands characteristics of the different 
functional groups present and their structural arrangement. In this respect a IR spectrum 
of a species helps elucidate structural details [90][91].     
 
        
3.3.2. Instrumentation of FTIR: 
FTIR spectrophotometry (figure 3-12) relies on an “interferometer”, which by turn is 
equipped with a beam splitter that splits the incident infrared beam into two: one reflects 
off of a fixed flat mirror at a fixed path length and the other from a mirror that moves at 
short distances to create a path difference between the two beams. These two reflected 
beams are then combined and interfered via the interferometer to include every single 
data about the incoming infrared frequency in a simultaneous fast manner. The produced 
signal is interpreted, through the application of a Fourier Transform resulting in a spectral 
plot of intensity versus wavenumber/frequency, reflecting the absorbing species structural 
information [87][95]. 
 
 
 
Fig 3-12. Principle of FTIR spectrometer operation [95]. 
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The analyzed samples could be a liquid, solid or gas. Sample holders (for liquids and 
gases) must be IR transparent and are typically composed of a alkaline metal halide. Solid 
samples are typically prepared by the KBr pellet technique where a mixture of 2-3 mg of 
the sample with 0.5-1 g of KBr is pressed into a transparent disk [96].  
 
3.4. Scanning Electron Microscopy (SEM) 
The SEM was invented 50 years ago, and now is a widely used scientific technique in 
metallurgy, geology, biology, medicine and many other fields, since it is capable of 
providing a nano-scale resolution with a good depth of field, giving information about the 
morphology, structures and chemical compositions and many other features [97][98].  
3.4.1. Principles of SEM: 
The SEM generates an accelerated beam of electrons from a suitable cathode source that 
passes through a set of condenser and objective lenses to decrease its cross section. The 
spot-like electron beam scans the surface of the sample in a vacuumed atmosphere, and 
an image is formed by collecting various signals reflected from the different interactions 
between the electron beam and the sample [97][98][99].  
 
There are two types of interactions that are responsible for an image formation: elastic 
and inelastic interactions. In the elastic interactions, electrons are generated from the back 
scattering of the incident electron beam by the outer electrons of a sample specimen 
having the same energy, at an angle greater than 90°, and giving an image of the sample’s 
depth. In inelastic interaction, the incident electron beam interacts with the specimen’s 
outer electrons, leading to the generation of secondary electrons from a depth of 5 nm 
below the surface, giving an image of the sample surface. In addition, other signals 
generated from the interaction between the electron beam and the sample such as X-ray 
emission, Auger electrons and cathodoluminescence can be used for additional 
compositional information about the sample, as shown in figure (3-13) [99][100][101]. 
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Fig 3-13. Illustration of the different signals obtained from hitting the sample specimen with the incident 
electron beam [99].  
 
3.4.2. Instrumentation of SEM:  
The SEM (figure 3-14) is equipped with an electron gun that produces an electron beam 
at a high voltage, with a small spot size and low energy dispersion. The electron beam 
then passes through the anode aperture into a lens system that focuses it onto the sample. 
The sample is placed in a chamber at high vacuum so as to prevent specimen 
contamination and interference of gas phase scattering. To obtain a clear image, the 
samples must be  electrically conductive; because they exhibit high electron density, 
increasing the emission of secondary electrons, that are responsible for producing a 
strong image, and otherwise, it is sputter-coated with a conductive metal such as gold, 
silver or palladium [97][100][101]. 
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Fig 3-14. Diagram of the scanning electron microscope (SEM) [100]. 
 
3.5. Zetasizer analyzer 
3.5.1. Principle of Zetasizer:  
The Zetasizer analyzer is capable of measuring both the size and zeta potential of a 
particle.  
The zetasizer measures the zeta potential, by applying an electric field to the liquid in 
which the particles are suspended (electrophoresis). These particles would move towards 
the electrode of opposite charges (attractive force), and the viscosity of the liquid 
surrounding the particles will act as an opposing force, resulting in an equilibrium state, 
that ends up in the particles moving at a constant velocity. This velocity is known as 
electrophoretic mobility, which is measured directly by an equipped laser technique 
called Laser Doppler Velocimetry (LDV) [102][103]. The electrophoretic mobility is 
translated to zeta potential by applying Henry’s law (equation 6) as follows: 
   
          
  
          eq.6 
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Where, ʑ is the zeta potential, UE is the electrophorectic mobility,   is dielectric constant, 
η  viscosity, and  (  ) is Henry’s function (≈1) [102][103]. 
 
As for particles’ size function, which is the main concern in this research is to be 
elaborated in details. The zetasizer measures the particle sizes via dynamic light 
scattering (DLS) technique, which measures the particles’ Brownian motion (collision of 
particles with the surrounding liquid)  and relates it to their sizes. It begins by directing a 
laser onto the  particles, which by turn scatters the light. The scattered light is then 
collected at a screen held close to the particles, to give a speckle pattern of bright and 
dark areas as in figure 3-15. To determine the particle sizes, the DLS compares first the 
intensity signals of a particular part of the speckle at a time point (t), to another signal at a 
later time (t+ δt), but over  a very small time scale in the order of 1 to 10’s milliseconds, 
in order to have a good correlation between the signal intensities over time. However, the 
suspended particles are not stationary due to Brownian motion, which leads to fluctuation 
of the intensities of the bright and dark areas in the speckle pattern. Therefore, the size 
particle is related to the rate of correlation decay: where small particles have fast 
correlation decay than large ones as seen in figure 3-16, because of their motion speed 
differences [102][103]. 
 
Fig 3-15. A screen with a speckle pattern of bright and dark areas [102]. 
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Fig 3-16. Correlation function of small and large particles over time [102]. 
 
The Zetasizer software uses algorithm to use the collected information of the correlation 
function to calculate the size distribution and displays it in the form of a graph as shown 
in figure 3-17, where X-axis represents the size distribution and Y-axis represents the 
relative intensity of scattered light [102][103].  
 
 
 
Fig 3-17. A typical size distribution graph [102]. 
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3.5.2. Instrumentation of Zetasizer:  
The DLS system consists of six main parts (figure 3-18): the laser source, which 
illuminate the particles that are suspended inside a cell. The intensity of the scattered light 
is then measured by the detector. However, the intensity of light should be within a 
certain range for the detector to measure, therefore, the system is equipped with an 
attenuator to adjust the intensity of the scattered light. The scattered light is then passes to 
a digital signal processor know as a correlator; which detects the correlation between the 
signal intensities at successive time intervals. The correlation information is then 
transferred  to the computer to produce a size distribution related data [102][103].  
 
 
Fig 3-18. A schematic description of the Zetasizer analyzer [102]. 
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4. Materials and Methods 
 
4.1. Materials  
High purity materials were purchased. Zinc nitrate hexahydrate (98%), Aluminum nitrate 
nonahydrate (≥98%), Sodium hydroxide (≥98%), sulfuric acid (95-97%), hydrochloric 
acid (37%), potassium permanganate (> 99%), copper sulphate pentahydrate (>98%), 
acetic acid (99.8%) and Phosphoric acid (85 %) were purchased from Sigma-Aldrich 
(Germany). Graphene nanopowder (11-15 nm) was purchased from SkySpring 
Nanomaterial (USA). Hydrogen peroxide (30%) was purchased from Merck (Germany), 
sodium acetate trihydrate (99.7%) was purchased from Fischer scientific, and ethanol 
(99.9%) was purchased from Carlo Erba (Italy). Alendronate sodium in trihydrate form 
(97%) was purchased from Alfa Aesar (Germany). 
 
4.2. Preparation of pristine LDHs 
Two different cationic ratios of Zn-Al LDH: (Zn
2+
: Al
3
) of 2:1 and 3:1, in their nitrate 
forms were prepared, by co-precipitation, following the procedure described elsewhere 
[104]: 
The two Zn-Al-NO3 LDH systems were prepared by mixing 0.1 M Zn(NO3)2.6 H2O with 
0.1 M Al(NO3)3.9 H2O, with ratios of 2:1 (30 ml:15 ml) or 3:1 (30 ml:10 ml). The 
mixture was then co-precipitated at room temperature and while maintaining the pH at 7, 
by the drop-wise addition of 2 M NaOH [1][6]. The mixture was magnetically stirred 
throughout the reaction, with nitrogen gas bubbling into the mixture solution to expel any 
dissolved carbon dioxide and thus preventing the intercalation of carbonate ions. The 
produced precipitate was then filtered using Whatman® filter paper, grade 1, with 11 μm 
pore size, followed by washing several times with de-ionized water to remove any 
impurities. The precipitate was then dried at 80°C overnight. This resulted in samples 
Zn2-Cp and Zn3-Cp for the 2:1 and 3:1 Zn
2+
:Al
3+
 LDH compositions respectively. 
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4.3.  Oxidation of G powder 
 
The oxidation of G followed the modified Hummer’s method with slight modifications 
[18]. A 9:1 mixture of concentrated H2SO4/H3PO4 (360 ml:40 ml) was added to a mixture 
of  G (3 g.) and KMnO4 (18 g.). The mixture was heated to 50°C, and then magnetically 
stirred for 12 hours. The mixture was then cooled to room temperature, poured to 400 ml 
of crushed ice (to have a mixture of the ice, G and acids), and then 3 ml of 30% H2O2 was 
added to it. It was then passed through a metal sieve (pore size: 300 μm) to remove any 
impurities or aggregates, centrifuged (Fischer Scientific Centrific Model 228) for one 
hour at 1129 rpm (RCF (10)=1.12×Radius(7mm)×(rpm/1000)
2
), and the supernatant was 
decanted. A purification process was then carried out on the solid product by successive 
washing with 200 ml deionized water, 200 ml 37% HCL, and twice with 200 ml ethanol. 
After each wash, the mixture was centrifuged and the supernatant was decanted. The 
resultant solid material was dried in a vacuum oven overnight [18].  
 
4.4.  Preparation of G and GO/LDH hybrids 
 
Hybrids of G and GO/Zn-Al-NO3, were prepared by co-precipitating the LDH in the 
presence of a dispersion of the G or GO. The choice of weight percentage (% w/w) of G 
or GO in total hybrid weight, and the concentration of the intercalating solution were 
based on their effect on the crystallinity of the LDH hybrid.  
 
4.4.1. Determining the optimum GO weight percentage in the hybrid 
(%w/w): 
 
In this step, different % wt of GO were intercalated into the co-precipitated Zn-Al-NO3 
LDH with cationic ratio (Zn
2+/
Al
3+
) of 2:1. 
 
Procedure  
Solutions A: 10 mg, 30 mg, or 70 mg of GO were first sonicated in small volumes of 
deionized water, till complete dispersion was achieved and a light brown suspension was 
obtained. The volumes were then completed to 250 ml with deionized water.  
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Solution B: A mixture of the metal cations was prepared with 0.1 M Zn (NO3)2.6 H2O 
and ml 0.1 M Al (NO3)3.9 H2O with a ratio of 2:1 (30 ml:15 ml). 
Solution B was then added drop wise to each of solutions A together with dropwise 
addition of 2 M NaOH at room temperature and while maintaining a pH 7 [1][6].The 
mixtures were magnetically stirred throughout the reaction, with nitrogen gas bubbling 
into the mixture solution to expel any dissolved carbon dioxide and avoid the 
intercalation of carbonate ions. The produced precipitates were then filtered using 
Whatman® filter paper, grade 1, with 11 μm pore size, washed several times with de-
ionized water to remove any impurities and dried overnight in the oven at 80°C. This 
resulted in LDH-GO hybrids with 2 % wt (for 10 mg GO dispersed in solution A), 6.2 % 
wt, (for 30 mg GO dispersed in solution A), and 13.4 % wt (for 70 mg GO dispersed in 
solution A) of GO. 
The 2 % wt GO showed the best XRD results, regarding the crystallinity of the LDH as 
would be discussed in the following chapter, and was thus chosen for the preparation of 
all LDH-GO and LDH-G hybrid samples.    
 
4.4.2. Determining the optimum volume for the G and GO dispersion 
solutions for the preparation of the LDH-G and LDH-GO 
hybrids: 
  
  The LDH hybrid composition as selected to be 2% (w/w) in G or GO, as explained above. 
Different volumes for the G and GO dispersion solutions were investigated for the 
formation of the LDH-G and LDH-GO hybrid to identify the optimum volumes. Both 
metal cationic ratios (Zn
2+
:Al
3+
) of 2:1 and 3:1 for the LDH were used. Table 4-1, 
summarizes the amounts and volume for different samples used in this investigation.   
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Table 4-1. G and GO/Zn-Al-NO3 hybrids prepared with different concentrations of the G and GO 
suspension/solution. 
 
 
 
Procedure: 
Solutions A: different amounts of G or GO were used for the suspension in different 
volumes: 0.04, 0.1, 0.2, 0.4 mg/ml in 250, 100, 50 and 25 ml volumes respectively. The 
G or GO was first sonicated in small volume of deionized water to obtain a homogenous 
suspension, free of agglomerates in case of G, and a clear light brown suspension in case 
of GO, and then the volumes were completed with deionized water. 
Solution B: a mixture of the metal cations was prepared with 0.1 M Zn (NO3)2.6 H2O 
and ml 0.1 M Al (NO3)3.9 H2O with a ratio of 2:1 (30 ml:15 ml) or a ratio of 3:1 (30 
ml:10 ml). 
Solution B was added dropwise to each of solutions A together with dropwise addition of 
2 M NaOH at room temperature and while maintaining a pH 7 [1][6]. The mixtures were 
magnetically stirred throughout the reaction, with nitrogen gas bubbling into the mixture 
solution to expel any dissolved carbon dioxide and avoid the intercalation of carbonate 
ions. The produced precipitates were then filtered using Whatman® filter paper, grade 1, 
with 11 μm pore size, washed several times with de-ionized water to remove any 
impurities and dried overnight in the oven at 80°C. This resulted in LDH-G and LDH-GO 
hybrids with 2 % wt of G or GO, as per Table (4-1). 
As the different volumes of G or GO dispersion solutions did not show any impact on the 
hybrid samples produced, regarding differences in crystallinity (as would be discussed  in 
Molar ratio 
( M
2+
: M
3+
) 
for the LDH 
Amount of dispersed G (mg/ml) Amount of dispersed GO (mg/ml) 
        
0.04 0.1 0.2 0.4 0.04 0.1 0.2 0.4 
2:1 
Zn2-
G.04-Cp 
Zn2-
G.1-Cp 
Zn2-
G.2-Cp 
Zn2-
G.4-Cp 
Zn2-
GO.04-Cp 
Zn2-
GO.1-Cp 
Zn2-
GO.2-Cp 
Zn2-
GO.4-Cp 
3:1 
Zn3-
G.04-Cp 
Zn3-
G.1-Cp 
Zn3-
G.2-Cp 
Zn3-
G.4-Cp 
Zn3-
GO.04-Cp 
Zn3-
GO.1-Cp 
Zn3-
GO.2-Cp 
Zn3-
GO.4-Cp 
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the following chapter), the largest solution volume (corresponding to the lowest 
dispersion concentration) would be therefore used. This larger volume would ensure 
easier dissolution of the drug to be loaded in these hybrids.    
 
4.5. Loading of alendronate sodium 
Alendronate sodium was loaded into the different host systems: pristine Zn-Al-NO3 
LDHs and the LDH-G and LDH-GO hybrids, and the different loading efficiencies of 
each of the systems investigated. Drug loading was conducted by co-precipitation and 
ion-exchange, as described elsewhere [104]. 
 
4.5.1. Co-precipitation: 
Table 4-2 The intercalated systems with alendronate sodium prepared by co-precipitation. 
 
Procedure: 
A- Preparation A-Zn2-Cp and A-Zn3-Cp hybrids: 
Solution A: known amount of alendronate sodium (0.0005 moles) was dissolved in a 
total volume of 250 ml of deionized water to have a drug concentration of approximately 
0.002 M.  
Solution B: a mixture of metal cations was prepared with 0.1 M Zn (NO3)2.6 H2O and 0.1 
M Al (NO3)3.9 H2O with a ratio of 2:1 (30:15 ml) for A-Zn2-Cp, or a ratio of 3:1 (30:10 
ml) for A-Zn3-Cp.  
 
Drug’s name 
Drug’s molar 
concentration 
 
Molar ratio  
(M2+: M3+) 
 
Intercalated system Sample code 
Alendronate 
sodium  
0.002 M  
2:1 
Zn-Al-NO3 A-Zn2-Cp 
Zn-Al-NO3/G A-Zn2-G-Cp 
Zn-Al-NO3/GO A-Zn2-GO-Cp 
3:1 
Zn-Al-NO3 A-Zn3-Cp 
Zn-Al-NO3/G A-Zn3-G-Cp 
Zn-Al-NO3/GO A-Zn3-GO-Cp 
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Solution B was added dropwise to solution A together of dropwise addition of 2 M NaOH 
at room temperature and while maintaining a pH 7 [1][6]. The mixtures were 
magnetically stirred throughout the reaction, with nitrogen gas bubbling into the mixture 
solution to expel any dissolved carbon dioxide and avoid the intercalation of carbonate 
ions. The produced precipitates were then filtered using Whatman® filter paper, grade 1, 
with 11 μm pore size, washed several times with de-ionized water to remove any 
impurities and dried overnight in the oven at 80°C. This resulted in samples A-Zn2-Cp 
and A-Zn3-Cp as presented in Table (4-2). 
 
 
B- Preparation of A-Zn2-G-Cp, A-Zn3-G-Cp, A-Zn2-GO-Cp, and A-Zn3-GO-
Cp: 
 
Solution A: a known amount of alendronate sodium (0.0005 moles) was dissolved in a 
total volume of 250 ml of deionized water to have a drug concentration of approximately 
0.002 M. An amount of G or GO was dispersed in the drug solution to result in a 2%wt of 
G in the LDH-G hybrid or of GO in the LDH-GO hybrid. The mixtures were sonicated 
till a homogenous, agglomerate-free suspension was produced in the case of G, and a 
clear light brown solution was obtained in the case of GO. The mixture was then left to 
stir for 24 hours. 
Solution B: a mixture of metal cations was prepared with 0.1 M Zn (NO3)2.6 H2O and 
0.1 M Al (NO3)3.9 H2O with a ratio of 2:1(30 ml:15 ml) for A-Zn2-G-Cp and A-Zn2-GO-
Cp or a ratio of 3:1 (30 ml:10 ml) for A-Zn3-G-Cp and A-Zn3-GO-Cp.  
Solution B was added dropwise to solutions A together of dropwise addition of 2 M 
NaOH at room temperature and while maintaining a pH 7 [1][6]. The mixtures were 
magnetically stirred throughout the reaction, with nitrogen gas bubbling into the mixture 
solution to expel any dissolved carbon dioxide and avoid the intercalation of carbonate 
ions. The produced precipitates (containing the drug) were then filtered using Whatman® 
filter paper, grade 1, with 11 μm pore size, washed several times with de-ionized water to 
remove any impurities and dried overnight in the oven at 80°C. This resulted in samples 
A-Zn2-G-Cp, A-Zn2-GO-Cp, A-Zn3-G-Cp and A-Zn3-GO-Cp as presented in Table (4-
2). 
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4.5.2. Ion- exchange: 
Table 4-3. The intercalated systems with alendronate sodium prepared by ion-exchange. 
 
Procedure:  
A known amount of alendronate sodium (0.0005 moles) were dissolved in a total volume 
of 50 ml of deionized water to have a drug concentration of approximately 0.01 M. It is 
important to note that a smaller total volume with a higher concentration of the drug was 
used for the ion-exchange (as compared with that used for co-precipitation) in order to 
allow for an efficient ion-exchange process.  
Portions of 100 mg of previously prepared Zn2-Cp, Zn3-Cp, Zn2-G.04-Cp, Zn2-GO.04-
Cp, Zn3-G.04-Cp and Zn3-GO.04-Cp were dispersed in the drug solution and sonicated 
till complete dispersion (when a white suspension is formed and no solid residues), the 
pH was then adjusted to 7 by the dropwise addition of 2 M NaOH [1][6]. The mixtures 
were magnetically stirred under nitrogen bubbling into the mixture for 24 hours to allow 
ion-exchange to take place. The produced suspensions were then vacuum filtered through 
a Whatman® nylon filter membrane of pore size 0.45 μm, in order to prevent the loss of 
the low yield precipitates, which were then dried overnight in the oven at 80 °C. This 
resulted in samples A-Zn2-IE, A-Zn2-G-IE, A-Zn2-GO-IE, A-Zn3-IE, A-Zn3-G-IE, and 
A-Zn3-GO-IE, as presented in Table (4-3). 
 
 
 
Drug’s name 
Drug’s molar 
concentration 
 
Molar ratio  
(M2
+
: M3
+
) 
 
Intercalated system Sample code 
Alendronate 
sodium  
0.01 M 
2:1 
Zn-Al-NO3 A-Zn2-IE 
Zn-Al-NO3/G A-Zn2-G-IE 
Zn-Al-NO3/GO A-Zn2-GO-IE 
3:1 
Zn-Al-NO3 A-Zn3-IE 
Zn-Al-NO3/G A-Zn3-G-IE 
Zn-Al-NO3/GO A-Zn3-GO-IE 
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4.6. Characterization 
The pristine LDHs, LDH-G, LDH-GO systems, and the drug-loaded systems were 
characterized by XRD, FTIR, SEM, and Zetasizer analyzer, while the loaded and released 
drug from the systems were quantified by UV/Vis spectrophotomerty.  
 
4.6.1. Powder X-ray Diffraction (PXRD): 
The powder X-ray diffraction patterns of the samples were obtained using a D8 Bruker 
X-ray diffractometer, which was operated at 40 KV and 30 mA, and using Cu as the 
anode target, producing Kα-X-rays of high intensity with a wavelength of 0.1542 nm. 
The patterns were detected at 2-theta range between 3° to 80°  with a step size of 0.030°, 
and a step time 3 seconds.  
4.6.2. Fourier Transform Infrared Spectroscopy (FTIR): 
The FTIR spectra of the samples were obtained using a Thermo-scientific Nicolet 380 
Fourier Transform Infrared spectrophotometer, using the KBr pellet method. The KBr 
pellets were prepared by grinding and mixing a ratio of 1:100 (sample mass: KBr mass), 
which was then compressed by a hydraulic pressure at a pressure of 1400 KPa. The FTIR 
spectra obtained presented a plot of wave number (4000-500 cm
-1
) against % 
transmittance. 
4.6.3. Scanning Electron Microscope (SEM): 
The morphological images of the samples were obtained by using Leo Zeiss supra field 
emission scanning electron microscope (FESEM). The instrument was operated at 23 
KV. The samples were conductive due to the presence of Zn and Al metals in the LDH 
and graphene, and therefore, there was no need for a coating layer.   
 
4.6.4. Ultraviolet/Visible (UV/Vis) spectroscopy: 
The amount of drug loaded or released was quantified using a Varian Cary 500 UV-Vis 
NIR double-beam spectrophotometer. The absorbance of the drug loaded was detected at 
λmax of 228 nm, while that of released drug was detected at 233 nm. The drug solution 
concentration values were determined from pre-constructed calibration curves (please 
refer to Appendix A). 
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Alendronate sodium lacks a detectable chromophore, which makes it difficult to be 
directly detected. However, since, alendronate sodium exhibits a metal-complexing 
property, derivatization of alendronate sodium by introducing a UV- active metal is 
typically used to allow its spectroscopic detection. Alendronate sodium forms a stable 
complex with copper (II) (Cu
2+
) ions, in acidic medium, having a 1:1 stoichiometry, that 
is detectable by UV/Vis spectrophotometry, which is presented as follows in equation (7):  
ABP + Cu 
2+
 
    
  ABP-Cu     eq.7 
Where ABP stands for alendronate sodium bisphosphonates [107][108]. As long as the 
concentration of the alendronate sodium in the sample is higher than that of  Cu
2+,
 the 
increase in the absorbance is proportional to the increase in concentration of ABP-Cu 
complex, but at higher concentration of Cu
2+,
 alendronate sodium is saturated with Cu
2+
, 
and the increase in absorbance is only proportional to the increase in the concentration of 
Cu
2+
 [108]. However, at constant concentration of Cu
2+,
 the saturation effect is negligible 
over a limited concentration range of alendronate sodium, and a linear relation between 
the absorbance and the concentration of alendronate sodium is obtained. Therefore, for 
the determinations here, the drug was derivatized as described by Walash et al. [107]. 2 
ml of a 2 mM copper (II) sulfate solution together with 2 ml of 5 mM acetate buffer (pH 
5, adjusted with acetic acid) were added to 2 ml of the alendronate sodium solution. The 
volume was completed to 25 ml using deionized water. In case of concentration 
determination in SGF (simulated gastric fluid), 2 ml of SGF were added to the solution 
mixture before completing to 25 ml. The concentration of alendronate sodium solutions 
to be detected were always kept in the range of 2-40 μm [107][108]. 
 
4.6.5. Zetasizer analyzer  
The particles size of the prepared samples were determined by Zetasizer analyzer (Image 
3-1) (Nano-ZS90) from Malvern Instruments. Very small amount of the sample powder 
were dispersed in about 1ml deionized water and then analyzed by dynamic light 
scattering, with 90° scattering optics  at room temperature.  
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4.7. Determination of alendronate sodium loading 
 
The loaded amount of drug, which includes both intercalated and adsorbed species, was 
determined based on the fact that LDH is degradable in acidic media (stomach), and 
therefore, the loaded drug could be recovered and detected after dissolving the LDH in 
acid [105]. A known mass (50 or 100) mg of the drug-loaded  systems were dissolved in 
a 10 ml of stimulated gastric fluid (SGF). The SGF stock was prepared according to the 
United States pharmacopeia (USP) 29: 2 g sodium chloride and 7 ml HCl were mixed 
together and the volume completed to 1000 ml by deionized water. The final pH was 1.2. 
The free drug was then detected by UV/Vis spectrophotometer at λmax 228 nm, and the 
concentration was determined using a pre-constructed calibration curve in SGF (please 
refer to Appendix A), following the procedure described in section 4.6.4. 
 
 
4.8. In- vitro drug release   
  
The in-vitro release study of alendronate sodium was performed in water medium as 
described in USP 29 for alendronate sodium solid dosage form. The dissolution 
procedure, needed to apply sink conditions. These are defined in the USP 29 as the 
volume of medium at least three times that required to form a saturated solution of the 
drug. Taking in consideration that the solubility of alendronate sodium in water is 10 
mg/ml [106], a known mass of the loaded system (50 to 100 mg with predetermined drug 
loaded amounts) was suspended in 10 ml deionized water, and placed in a thermostated 
water bath shaker at 37 °C and 50 strokes/min. The absorbance of the released drug was 
detected at different time intervals  
( 0.16, 0.5, 1, 2, 4, 6, 18, and 24 hrs) with UV/Vis spectrophotometer at λmax 233 nm, and 
the concentration was determined using a pre-constructed calibration curve in deionized 
water (please refer to Appendix A), following the procedure described in section 4.6.4.  
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 5. Results and Discussion 
 
5.1. Pristine LDHs 
5.1.1. XRD: 
Figure 5-1 presents the XRD spectra for Zn2-Cp and Zn3-Cp, showing their successful 
preparation by co-precipitation, that is emphasized by the presence of the characteristic 
reflections for LDHs. These reflections are divided into two main types: strong basal and 
intense reflections at low 2θ angles, and other asymmetric broader reflections at higher 2θ 
angle values [1][6][109]. The sharp reflections are associated to diffraction by planes 
(003), (006), and (009). The basal spacing d(003), which is equal to one interlayer distance 
plus the thickness of one brucite-like layer can be calculated directly from the peak 
position of the (003) peak using Bragg’s law (equation.1, sector 3.1.1). Thus, the exact 
interlayer distance is easily calculated by subtracting the thickness of the brucite-like 
layer (estimated as 4.77 Å as stated by Miyata) [110]. These reflections are also useful in 
calculating the lattice parameter (c) from either the position of the first peak (equation 8 
and 9):  
c꞊ 3d(003)           eq.8 
or the average of the three peak positions:  
c=d(003)+ 2d(006)+ 3d(009)        eq.9 
The (009) reflection is usually overlapped with non basal reflections and broad due to 
disorders of the interlayer anions and water molecules. While the reflections at higher 
angle values (around 2 θ≈ 60º), are useful for the determination of the lattice parameter 
(a): as a= 2d(110); whose value is equal to the distance between two metal cations, and 
thus, reflecting the radii of the cations [1]. As for the characteristic reflections at the 
intermediate angles: (012), (015) and (018), these are used to determine the stacking 
sequence of the layers, and with the values of a and c, are indexed as 3R stacking 
polytype with hexagonal symmetry [1].  
The prepared samples showed the as-mentioned characteristic reflections, agreeing with 
literature [111], and  their lattice parameters, d-spacing and interlayer distances are 
summarized in table (5-1) . The (003) reflection in the case of Zn2-Cp had shifted slightly 
to a lower 2 θ (≈9.7 º) than that of Zn3-Cp (≈ 10.3 º), giving d-spacing values of 9.1 Å 
and 8.6 Å respectively. Since, c value is greatly dependent on the size, charge and the 
orientation of the interlayer anions, it increases with the increase of the interlayer 
distance. In this case, the increase in the basal spacing was due to the decrease of the 
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metal cations ratio (high x value), indicating higher positive charge density in the brucite-
like layers, accommodating more nitrate anions to neutralize the positive charges. These 
cannot fit in a parallel manner in the interlayer space and hence, are tilted, giving slightly 
larger d-spacing and c value [111][112]. The increase of the charge density in sample 
Zn2-Cp is also reflected on the increase of the peaks’ intensities compared to sample 
Zn3-Cp, with a very good agreement with literature reported by Seftel et al [112]. On the 
other hand, the value of parameter (a) for both samples is almost the same, which 
indicates its independency of the metal cationic ratio [6].  
 
 
 
 Fig 5-1. XRD patterns of Zn2-Cp (a), and Zn3-Cp (b). 
 
 
Table 5-1. The lattice parameters, d-spacings and interlayer distances of Zn2-Cp and Zn3-Cp. 
  
Sample d spacing (Å) Lattice parameters 
(Å) 
Interlayer 
distance (Å) 
d(003) d(110) 
 
c 
 
a 
  
Zn2-Cp 9.1 1.53 27.3 3.06 4.33 
Zn3-Cp 8.6 1.52 25.8 3.04 3.83 
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5.1.2. FTIR: 
Figure 5-2 shows the IR spectra of Zn2-Cp and Zn3-Cp. Both show a broad absorption 
band at around 3400 cm
-1
, which is attributed to the stretching vibrations of the hydroxyl 
groups (O-H) in the brucite-like layers or the adsorbed water molecules [6][113]. The 
peak 1612 cm
-1
 is due to the H-O-H bending vibration of the interlayer water molecules. 
A very sharp characteristic peak at 1384 cm
-1
 is attributed to the nitrate group vibration 
[113]. Peaks showing at low frequency regions: around 800, 600 and 426 cm
-1
, are 
attributed to vibrations of the metal-oxygen (M-O) and metal-oxygen-metal (M-O-M) 
bonds in the brucite-like layers [113]. 
Fig 5-2. FTIR spectra of Zn3-Cp (a) and Zn2-Cp (b) pristine LDHs. 
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5.1.3. SEM: 
Figure 5-3 shows the SEM image of the general structure of Zn-Al-NO3 LDHs, clearly 
showing the flake-like structure of the layers [114]. 
 
Fig 5-3. SEM image of pristine Zn-Al-NO3 LDH. 
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5.2.  Oxidation of G powder 
 
5.2.1. XRD:  
The successful oxidation of G into GO sheets, using improved Hummer’s method, was 
proven by the appearance of GO characteristic XRD reflections as shown in figure (5-4). 
Prior to oxidation, the G showed a very sharp (002) peak at 2θ≈26.15°, having an 
interlayer spacing of 3.4 Å. Post-oxidation, the (002) peak was greatly shifted to a lower 
2θ value of 9.1°, having an interlayer spacing of 9.7 Å. This increase in the interlayer 
spacing is attributed to the introduction of oxygenated functional groups at both sides of 
the G sheets. The small broad peaks at higher 2θ values indicate the presence of traces 
from the starting G powder [17][21][23]. 
 
 Fig 5-4. XRD patterns of G (a), and GO (b). 
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5.2.2. FTIR:  
As shown in figure 5-5,  some important vibration bands appeared upon G oxidation, that 
are related to the introduced oxygenated groups. These vibrations are: O-H stretching 
vibration, appearing at around 3400 cm
-1
. These hydroxyl groups are attributed to both 
carboxylic acid groups (COOH) and adsorbed water molecules, the band at 1612 cm
-1
 is 
also an indication of the O-H bending vibration of the adsorbed water molecules. Bands 
appearing at 1726 cm
-1
 is attributed to C=O stretching vibrations, from COOH, ketone or 
quinone groups. C-O vibration appears at 1228 cm
-1
, and C-O-C stretching vibration 
appears at 1170 cm
-1
 [20][21][23]. 
 
 
Fig 5-5. FTIR spectra of G (a) and GO (b). 
 
 
5.2.3. SEM: 
Figure 5-6 represents the SEM images for the surface morphology of G prior and post 
oxidation. Prior oxidation, G, showed aggregations of several stacked layers, giving rise 
to a rough surface appearance. While, post-oxidation the surface of GO sheets was 
smoother, showing less aggregates, and very few stacked layers; which indicates the 
successful exfoliation of the G by its oxidation [17][20][21][23].  
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Fig 5-6. SEM images of G (a), and GO (b). 
 
 
a 
b 
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5.3. Preparation of G/GO-LDH hybrids 
 
5.3.1. Determining the optimum GO weight percentage in the hybrid 
(%w/w): 
 
Figure 5-7 shows the XRD patterns of GO-LDH hybrids, prepared using LDH with 
M
2+
/M
3+
 ratio of 2:1 and different % wt of GO (2, 3.2, and 13.4 % wt). The intensity of 
the reflections at plane (003) and (006) become less intense and broader with the increase 
of the % wt of GO (2, 6.2, and 13.4 % wt respectively), which indicates that the GO 
affects the crystallinity (layer stacking) of the LDH. Therefore, the 2 % wt, was the 
percentage of choice for both G and GO to be incorporated in all G/GO-LDH hybrid 
samples as will be shown in the following parts. This minimizes the use of G or GO in 
the nanocomposite.  
 
Fig 5-7. GO-LDH hybrids prepared with GO: 2 % (a), 6.2 % (b) and 13.4 % w/w (c). 
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5.3.2. Determining the optimum solution volume for the G and GO 
dispersion for the preparation of the LDH-G and LDH-GO 
hybrids: 
 
A- XRD 
Figures 5-8 to 5-11 present the XRD patterns of G/GO-LDH hybrids, prepared by co-
precipitation using different G/GO concentrations (mg/ml) of a fixed amount of G or GO  
(2 % wt), with LDH of metal cations ratio (M
2+
/ M
3+
) of 2:1 and 3:1. The values of 
calculated d(003), d(110) and interlayer spaces of all samples are summarized in table 5-2. 
For samples prepared using LDH of M
2+
/ M
3+
 (2:1), neither the change of G nor the GO 
concentration has a noticeable effect on the value of d(003), interlayer space, or d(110). 
Same findings were observed among samples prepared by LDH of M
2+
/ M
3+
 ratio (3:1); 
the LDH parameters has not been affected by either G or GO. In addition the change of the 
M
2+
/ M
3+
 ratio of the LDH is of insignificance as well, but very slight increase of the 
interlayer space in case of 2:1 was observed, because of the higher positive charge density 
in the brucite-like layers that accommodates more nitrate anions for neutralization, causing 
this slight increase [111][112]. When the hybrids were compared to pristine LDH (2:1 and 
3:1) controls, the G and GO reflections disappeared and  were found to superimpose with 
those of the LDHs, because G and GO were incorporated in a small weight percentage 
from the total hybrid weight.  
All of the previous observations generally indicate that no intercalation of G or GO has 
taken place, and the hybrid is rather formed via adsorption on LDH surfaces. Moreover, 
the intensities of the peaks, which are related to the crystallinity of the LDH samples are 
not affected by the presence of G or GO. 
Based on the above, hybrid samples with the lowest concentration of G or GO (0.04 
mg/ml) were chosen for drug loading. This has two advantages: it minimizes the effect of 
G or GO on the LDH formation, and also ensures minimal possibilities of agglomeration 
between G or GO in the hybrid samples.  
71 
 
 
 Fig 5-8. XRD patterns of G (a), Zn2-Cp (b), Zn2-G.04-Cp (c), Zn2-G.1-Cp (d), Zn2-G.2-Cp (e), 
and Zn2-G.4-Cp (f). 
 
 
  Fig 5-9. XRD patterns of GO (g), Zn2-Cp (h), Zn2-GO.04-Cp (i), Zn2-GO.1-Cp (j), Zn2-
GO.2-Cp (k), and Zn2-GO.4-Cp (l). 
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 Fig 5-10. XRD patterns of G (a), Zn3-Cp (b), Zn3-G.04-Cp (c), Zn3-G.1-Cp (d), Zn3-G.2-Cp (e), 
and Zn3-G.4-Cp (f). 
 
Fig 5-11. XRD patterns of GO (g), Zn3-Cp (h), Zn3-GO.04-Cp (i), Zn3-GO.1-Cp (j), Zn3-GO.2-Cp (k), 
and Zn3-GO.4-Cp (l). 
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Table 5-2. The calculated d-spacings and interlayer spaces of prepared G/GO-LDH hybrids, with different 
concentrations of G and GO (mg/ml) and metal cations ratio of LDH. 
 
 
 
B- FTIR 
Figures from 5-12 to 5-15 are FTIR spectra of the prepared G/GO-LDH hybrids. The 
characteristic bands of pristine LDH are superimposed on those of G and GO. The 
characteristic broad band at around 3400 cm
-1
 is attributed to the OH group of the brucite-
like layers and the adsorbed water molecules as well as the OH groups of GO where 
applicable [20][113]. The band at around 1600 cm
-1
 is due to the H-O-H bending 
vibration of the interlayer water molecules. Highly intense nitrate band at around 1384 
cm
-1
, which proves the absence of intercalation of G or GO in the LDH interlayer space. 
The vibration bands appearing at lower frequencies (around 400, 600, and 800cm
-1
) are 
assigned to the M-O and M-O-M bonds of the brucite-like layer, which indicates that the 
G and GO have no effect on the brucite-like layers [113]. 
 
 
 
 
 
Sample  d-spacing 
 (Å) 
Interlayer 
space 
 (Å) 
Sample d-spacing  
(Å) 
Interlayer 
space  
(Å) 
 d (003) d (110) d (003) d (110)  
Zn2-G.04-Cp 8.6 1.54 3.89 Zn2-GO.04-Cp 8.8 1.53 4.03 
Zn2-G.1-Cp 9.0 1.53 4.29 Zn2-GO.1-Cp 8.7 1.53 3.99 
Zn2-G.2-Cp 8.8 1.54 4.10 Zn2-GO.2-Cp 8.8 1.54 4.03 
Zn2-G.4-Cp 9.0 1.53 4.23 Zn2-GO.4-Cp 8.8 1.54 4.03 
Zn3-G.04-Cp 7.8 1.54 3.03 Zn3-GO.04-Cp 8.7 1.53 4.01 
Zn3-G.1-Cp 9.0 1.53 4.26 Zn3-GO.1-Cp 9.0 1.54 4.23 
Zn3-G.2-Cp 9.0 1.54 4.26 Zn3-GO.2-Cp 8.9 1.54 4.13 
Zn3-G.4-Cp 9.0 1.53 4.23 Zn3-GO.4-Cp 8.9 1.53 4.13 
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 Fig 5-12. FTIR spectra of G (a), Zn2-Cp (b) Zn2-G.04-Cp (c), Zn2-G.1-Cp (d), Zn2-G.2-Cp (e), 
and Zn2-G.4-Cp (f). 
 
 Fig 5-13. FTIR spectra of GO (g), Zn2-Cp (h), Zn2-GO.04-Cp (i), Zn2-GO.1-Cp (j), Zn2-GO.2-
Cp (k), and Zn2-GO.4-Cp Cp (l). 
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 Fig 5-14. FTIR spectra of G (a), Zn3-Cp (b), Zn3-G.04-Cp (c) , Zn3-G.1-Cp (d), Zn3-G.2-Cp (e), 
and Zn3-G.4-Cp (f). 
 
 Fig 5-15. FTIR spectra of GO (g), Zn3-Cp (h),  Zn3-GO.04-Cp (i) , Zn3-GO.1-Cp (j), Zn3-GO.2-
Cp (k), and Zn3-GO.4-Cp (l). 
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 5.4. Loading of Alendronate sodium 
In this section, for each loaded system, the XRD results were analyzed for successful 
drug intercalation, followed by their FT-IR spectra to confirm the XRD findings. The 
systems were then tested for their loading efficiency, and those showing best intercalation 
results are tested for theirs in-vitro drug release behavior. 
5.4.1. Co-precipitation samples: 
 
A- XRD 
Figures 5-16 and 5-17 show the XRD patterns of samples A-Zn3-Cp, A-Zn3-G-Cp and 
A-Zn3-GO-Cp, which are prepared by co-precipitation using M
2+
/M
3+
 ratio of 3:1. All of 
the three samples showed an obvious shift of the (003) reflection to a lower 2θ value 
indicating an expansion in the d-spacing when compared to their corresponding 
precursors: Zn3-Cp, Zn3-G.04-Cp, and Zn3-GO.04-Cp respectively, as summarized in 
table 5-3. 
A-Zn3-Cp, (figure 5-16), showed a huge shift of the (003) reflection to a lower 2θ of 
4.8°; corresponding to an expansion of the d(003) from 8.6 Å to 18.3 Å. When 
subtracting the brucite-like layer thickness (4.77 Å), the interlayer space is calculated to 
be 13.5 Å [110]. The expansion of the interlayer space suggests the successful 
intercalation of alendronate sodium. The interlayer gallery (13.5 Å) is greater than the 
maximum height of one drug anion (6.1 Å) [115][116], suggesting drug intercalation in a 
bi-layered arrangement [55][61][104]. These results are similar to those reported for the 
intercalation of Ketoprofen, with the most comparable molecular size value (8.2 Å) in 
Mg/Al system, giving an interlayer distance of 17.2 Å, suggesting its intercalation as 
slightly tilted bi-layer [60]. In addition, the broadening of the reflections along the XRD 
pattern is an indication of decreased crystallinity post drug’s intercalation [61]. The 
calculated d value for plane (110) is 1.53 Å, which is almost the same as that of the 
precursor (1.52 Å), therefore, the brucite-like layers are not affected by the hosted drug 
[61]. 
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 Fig 5-16. XRD patterns of alendronate sodium (a),  pristine LDH Zn3-Cp (b), and A-Zn3-Cp (c). 
 
 
For samples A-Zn3-G-Cp and A-Zn3-GO-Cp (figure 5-17), the reflection at (003) shifted 
to lower 2θ values of 4.77° and 4.98°, giving an expansion of the d(003) of 18.5 Å and 
17.73 Å respectively when compared to their precursors, 7.8 and 8.7 Å respectively. 
Subtracting the brucite-like layer thickness (4.77 Å), the interlayer distances are 
calculated as 13.7 Å and 12.9 Å respectively [110]. The reflection peaks of the G or GO 
don’t appear, being superimposed by those of the LDH phase [117]. The expansion of the 
interlayer spacing can be explained by the successful intercalation of the drug in a bi-
layered arrangement (12.2 Å). While drug loaded on G or GO surface is probably 
adsorbed on the surface of the LDH. The preparation of a drug loaded G/GO-LDH 
nanocomposite by co-precipitation was not reported by others in the literature, but rather 
the loading of antibacterial benzyl penicillin by ionic exchange using solvent evaporation 
process has been reported. Their XRD results for GO-benzyl penicillin-LDH were similar 
to that of the benzyl penicillin-LDH, that by turn has shown a bi-layered arrangement of 
the drug (11.7 Å), attributed to the interlayer distance of 17.4 Å. The non significant 
effect of the GO on the drug-LDH reflection indicated its surface adsorption rather than 
intercalation [61]. 
The presence of G or GO may have prevented the proper stacking of the brucite-like 
layers during co-precipitation leading to a decrease in crystallinity, indicated by the 
broadening of the XRD reflections, especially that at plane (003) [6][55][61]. This is 
indeed more noticeable for sample A-Zn3-G-Cp, probably due to G tending to 
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agglomerate by π-π stacking, and thus preventing the layer stacking of the LDH. This is 
indicated by the slight increase in the interlayer space for this sample as compared to that 
of A-Zn3-GO-Cp [6][118][119].  
The calculated d values for plane (110), in both samples are the same as that of their 
precursors (1.54 and 1.53 Å respectively), which is an indication that the brucite-like 
layers remained unchanged and not affected by the presence of either G or GO [61]. 
 
Fig 5-17. XRD patterns of alendronate sodium (a), Zn3-G.04-Cp (b), A-Zn3-G-Cp (c), Zn3-GO.04-Cp (d), 
and A-Zn3-GO-Cp (e). 
 
 
Table 5-3. Comparison between the parameters of the loaded samples prepared by co-precipitation using  
metal cations ratio of 3:1 and their controls. 
 
Before drug loading After drug loading 
Sample 
precursor 
2θ 
(at 003 
plane) 
d-spacing 
 (Å) 
Interlayer 
space  
(Å) 
Loaded  
Sample 
2θ 
(at 003 
plane) 
d-spacing 
(Å) 
Interlayer 
space  
(Å) 
  d 
(003) 
d 
(110) 
 d 
(003) 
d 
(110) 
Zn3-Cp 10.3° 8.6   1.52 3.83 A-Zn3-Cp 4.8° 18.3 1.53 13.53 
Zn3-G.04-
Cp 
11.3° 7.8 1.54 3.00 
A-Zn3-G-
Cp 
4.8° 18.5 1.54 13.70 
Zn3-GO.04-
Cp 
10.1° 8.7 1.53 4.02 
A-Zn3-
GO-Cp 
5.0° 17.7 1.53 12.90 
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Figure 5-18 and 5-19, show XRD patterns of samples A-Zn2-Cp, A-Zn2-G-Cp and        
A-Zn2-GO-Cp, which are prepared by co-precipitation, using a M
2+
/M
3+
 ratio of 2:1. The 
samples were compared to their corresponding precursors: Zn2-Cp, Zn2-G.04-Cp and 
Zn2-GO.04-Cp respectively.  
The XRD pattern of A-Zn2-Cp (figure 5-18) shows an obvious collapse of the LDH 
layered structure. The very weak reflections at high 2θ values are attributed to the metal 
oxides of the disordered brucite like layers [104][111]. It is suggested that the ratio used 
for the M
2+
/M
3+
 (2:1), is rendering the brucite-like layers more positive than the 3:1 ratio, 
and therefore, the LDH structure would need to accommodate more negatively charged 
anions to neutralize these charges. However, the large size of the drug molecule cannot fit 
in the interlayers, and fails to neutralize the positively charged brucite-like layers and 
hinders its proper stacking, and thus resulting in the loss of the of layered structure of 
LDH [6][119].  
 
 Fig 5-18. XRD patterns of alendronate sodium (a), pristine LDH Zn2-Cp (b), and A-Zn2-Cp (c). 
 
 
 
The XRD patterns of A-Zn2-G-Cp and A-Zn2-GO-Cp (figure 5-19), show same XRD 
features as previous sample (A-Zn2-Cp), indicating the collapse of the LDH layered 
structure. All three samples (A-Zn2-Cp, A-Zn2-G-Cp, and A-Zn2-GO-Cp), show traces 
of reflections at high 2θ, that correspond to the metal oxide of the disordered brucite-
like layers [104][111].  
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 Fig 5-19. XRD patterns of alendronate sodium (a), Zn2-G.04-Cp (b), A-Zn2-G-Cp (c), Zn2-
GO.04-Cp (d), and A-Zn2-GO-Cp (e). 
 
 
 
B- FTIR  
Figure 5-20 shows the FTIR spectra of A-Zn3-Cp compared to its precursor (Zn3-Cp) 
and free alendronate sodium. The loaded system (A-Zn3-Cp) shows the pristine LDH 
characteristic broad band at around 3442 cm
-1
, that is attributed to the OH groups of the 
brucite-like layers and the adsorbed water molecules, as well as the OH group in the free 
alendronate sodium. This band overlaps with the stretching vibration band of N-H 
(primary amine) of the free alendronate sodium, that appears in the range of 3400-3250 
cm
-1 
[56][106][113]. The band at around 1641 cm
-1
 is due to the H-O-H bending vibration 
of the interlayer water molecules of the LDH. The decrease in intensity suggests a 
disturbance in the interlayer water molecules. The intensity of the nitrate band at 1383 
cm
-1 
in pristine LDH has noticeably decreased in the loaded sample (A-Zn3-Cp), 
indicating the displacement of the nitrate anions by alendronate sodium [113][120]. 
However, the incomplete disappearance of the band may indicate the presence of some 
retained nitrate anions [1]. The free drug shows distinctive bands between 925 and 1238 
cm
-1
, which are attributed to the stretching vibrations of C-O and P=O bonds. In the 
loaded sample, these peaks were shifted, and overlapped, giving a broader peak at around 
1118 cm
-1
. This suggests a hydrogen-bond interaction with the brucite-like layers 
[121][122]. The peaks appearing in pristine LDH at 576.6 and 971 cm
-1
, assigned to the 
M-O and M-O-M bonds of the LDH [113], are down shifted in the loaded sample from 
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their original frequencies (428, 606, 831 cm
-1
), to 576 and 971 cm
-1
,suggesting a guest-
host interaction between the drug and the OH groups of the brucite-like layers, which is 
also supported by their overlap with the 1118 cm
-1 
band of the loaded drug [113]. This 
confirms the successful intercalation of the alendronate sodium into the LDH interlayer, 
as has been suggested.   
 
Fig 5-20. FTIR spectra of A-Zn3-Cp (a), Zn3-Cp (b), and alendronate sodium (c). 
 
 
Figure 5-21 and 5-22 show the FTIR spectra of A-Zn3-G-Cp and A-Zn3-GO-Cp 
compared to their corresponding precursors Zn3-G.04-Cp and Zn3-GO.04-Cp  
respectively, as well as free alendronate sodium. Both loaded systems have same 
interpretation bands’ features as the above sample (A-Zn3-Cp) as follows: 
 OH broad band at around 3440 cm-1 ( that also corresponds to the COOH of GO in 
sample A-Zn3-GO-Cp). 
  H-O-H bending vibration band at around 1620 cm-1. 
  Nitrate band at around 1384 cm-1. 
 C-O and P=O stretching bands of alendronate sodium for sample A-Zn3-G-Cp and 
A-Zn3- GO-Cp at 1116 and 1114 cm
-1
 respectively. 
 M-O and  M-O-M vibration bands at around 600 and 940 cm-1. 
 
The decrease in the nitrate band intensity indicates its displacement with the drug. This 
decrease is more noticeable in these two samples (A-Zn3-G-Cp and A-Zn3-GO-Cp) than 
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that of A-Zn3-Cp, because the expansion of the interlayer spaces as observed in their 
XRD patterns indicates an increased amount of intercalated drug. The intercalation is also 
proven by the overlap and the shift of the alendronate sodium band giving a single broad 
band, and the down shift of M-O and M-O-M bands [113][121][122]. 
 
 Fig 5-21. FTIR spectra of A-Zn3-G-Cp (a), Zn3-G.04-Cp (b), and alendronate sodium (c). 
 
 
 Fig 5-22. FTIR spectra of A-Zn3-GO-Cp (a), Zn3-GO.04-Cp (b), and alendronate sodium (c). 
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Figure 5-23, shows the FTIR spectra of A-Zn2-Cp compared to its precursor Zn2-Cp and 
free alendronate sodium. As mentioned previously, the XRD result for A-Zn2-Zp, has 
shown a collapse in the LDH structure, with only traces of reflections corresponding to 
the disordered brucite-like layers. Therefore, the FTIR shows the characteristic peaks for 
the LDH as discussed previously, which mainly correspond to the brucite-like layers in 
addition to other features as follows:  
 OH vibration broad band at around 3440 cm-1. 
 H-O-H bending vibration band at 1640 cm-1. 
 Nitrate band at 1384 cm-1.  
 C-O and P=O stretching vibration bands of the alendronate sodium appears at 
1112 cm
-1
. 
 M-O and M-O-M vibration bands at 426 and 580 cm-1.
           
 
The nitrate band intensity is noticeable due to failure of intercalation. However, it is of 
low intensity than that of the precursor, due to the loss of the nitrate anions neutralizing 
the brucite-like layers. In addition, The presence of the characteristic band of the drug, 
indicates its presence in the LDH environment. This can possibly indicate the alendronate 
sodium adsorption on the surface of the brucite-like layers. Although most of the M-O 
and the M-OM bands are still at their original frequencies, one of which is down shifted 
and overlapping with that of the drug (1112 cm
-1
), which could  explain the presence of 
weak hydrogen bonding between the drug and the brucite-like layers [121][122].  
 
 Fig 5-23. FTIR spectra of A-Zn2-Cp (a), Zn2-Cp (b), and alendronate sodium (c). 
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Figure 5-24 and 5-25 show the FTIR spectra of A-Zn2-G-Cp and A-Zn2-GO-Cp 
respectively, which have the same FTIR features and interpretation as in previous sample 
(A-Zn2-Cp), as follows: 
 OH broad band at around 3440 cm-1.  
 H-O-H bending vibration band at 1630 cm-1. 
 Nitrate band at 1380 cm-1.  
 C-O and P=O stretching bands of the alendronte sodium at around 1110 cm-1.  
 M-O and M-O-M vibration bands  around 570 and 960 cm-1. 
The M-O and M-O-M bands in these two samples (A-Zn2-G-Cp and A-Zn2-GO-Cp), are 
all down shifted to around 570 and 960 cm
-1
, compared to previous sample (A-Zn2-Cp), 
which indicates the presence of stronger hydrogen bonding of drug loaded on the G or 
GO and brucite-like layers.  
 
 
Fig 5-24. FTIR spectra of A-Zn2-G-Cp (a), Zn2-G.04-Cp (b), and alendronate sodium (c). 
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 Fig 5-25. FTIR spectra of A-Zn2-GO-Cp (a), Zn2-GO.04-Cp (b), and alendronate sodium (c). 
 
 
5.4.2. Ion-exchange samples: 
 
A- XRD 
Figures 5-26 and 5-27 show the XRD patterns of samples A-Zn3-IE, A-Zn3-G-IE and A-
Zn3-GO-IE, which are prepared by loading the free drug dissolved in an aqueous media 
by ion exchange with the dispersed precursor Zn3-Cp, Zn3-G.04-Cp and Zn3-GO.04-Cp 
respectively. The parameters are calculated and summarized in table 5-4. 
XRD pattern of sample A-Zn3-IE (figure 5-26), shows a huge downshift of 2θ from 10.3° 
to 4.74°, to give a d(003) expansion of ≈18.62 Å, and by subtracting the brucite-like layer 
thickness (4.77 Å), the calculated interlayer distance is equal to 13.82 Å, suggesting the 
intercalation of the drug in a bi-layered arrangement [55][61][104]. The peak at (003) is 
broad and of low intensity, indicating disturbance of the layer stacking to some extent 
[6][55]. However, the reflections at (006), (012), and (110) suggest that the LDH 
structure somehow still keeps its integrity and is not completely distorted. The calculated 
d value for the (110) plane is 1.52 Å, which is as same as that of the precursor, indicating 
that the brucite-like layers are not affected during ion exchange [61]. These are similar to 
findings reported by Ambrogi et al. for the intercalation of diclofenac in Mg/Al LDH by 
ion exchange, suggesting their arrangement as bi-layers, which was indicated by the 
interlayer distance value compared to the drug molecule height [58]. The d-spacing 
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expansion value is also similar to those reported by literature (Michelle Chakraborti 
2011), for intercalation of alendronate sodium in Mg/Al LDH giving an interlayer 
distance of 12.8 Å [124]. 
 
 Fig 5-26. XRD patterns of alendronate sodium (a), pristine LDH Zn3-Cp (b), and A-Zn3-IE (c). 
 
 
The XRD patterns of samples A-Zn3-G-IE and A-Zn3-GO-IE (figure 5-27), show a very 
slight shift of the peak at plane (003) to a higher 2θ of 11.79° and 11.2°, corresponding to 
d-spacing values of 7.5 and 7.85 Å respectively. When subtracting the brucite-like layer 
thickness (4.77 Å), the calculated interlayer gallery heights are 2.73 and 3.09 Å for Zn3-
G.04-Cp and Zn3-GO.04-Cp respectively [110]. The interlayer gallery height is lower 
than the maximum height of one drug molecule (6.1 Å) [114][116]. Moreover, the size of 
carbonate is 1.31Å, which excludes the possibility of contamination with dissolved 
carbonate [6][102][123]. This therefore seems to indicate that no exchange reaction has 
taken place. The slight interlayer compaction could be due to the loss of some nitrate 
anions during the high contact with the solution (24 hr). In both samples, the significance 
of the reflections at (006), (012), and (110) suggests that the LDH structure still keeps its 
integrity and is not completely distorted [1][111].  The calculated d values for the (110) 
planes of both samples are 1.54 and 1.534 Å respectively, which indicates that the 
brucite-like layers are intact [61]. These findings were different than the previously 
mentioned study by Wang et al., reporting the preparation of GO-benzyl penicillin-LDH 
nanocomposite by ionic exchange using solvent evaporation process [61]. The 
nanocomposite have shown a successful intercalation of the drug in bi-layered 
arrangement, and surface adsorption of the GO. This difference is attributed to the 
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different preparation techniques used. Where the GO suspension is mixed with that of 
benzyl penicillin-LDH and allowed to evaporate under temperature [61]. While in this 
paper, the drug is rather mixed with as-prepared G or GO-LDH precursor, and allowed to 
stir for long period of time. 
 
 
Fig 5-27. XRD patterns of alendronate sodium (a), Zn3-G.04-Cp (b), A-Zn3-G-IE (c), Zn3-GO.04-Cp (d), 
and A-Zn3-GO-IE (e). 
 
 
 
Table 5-4. Comparison between the parameters of the loaded samples prepared by ion-exchange, using 
ametal cations ratio of 3:1 and their controls. 
 
 
 
Before drug loading After drug loading 
Sample 
precursor 
2θ 
(at 003 
plane) 
d-spacing  
(Å) 
Interlayer 
space  
(Å) 
Loaded  
Sample 
2θ 
(at 003 
plane) 
d-spacing 
(Å) 
Interlayer 
space  
(Å) 
  d 
(003) 
d 
(110) 
 d 
(003) 
d 
(110) 
Zn3-Cp 10.3° 8.6  1.52 3.83 A-Zn3-IE 4.7° 18.6 1.52 13.82 
Zn3-G.04-
Cp 
11.3° 7.8 1.54 3.00 
A-Zn3-G-
IE 
11.8° 7.5 1.54 2.73 
Zn3-GO.04-
Cp 
10.1° 8.7 1.53 4.02 
A-Zn3-
GO-IE 
11.2° 7.8 1.53 3.09 
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Figures 5-28 and 5-29 show the XRD patterns of samples A-Zn2-IE, A-Zn2-G-IE and A-
Zn2-GO-IE, which are prepared by loading the free drug dissolved in an aqueous media 
by ion exchange with the dispersed precursor Zn2-Cp, Zn2-G.04-Cp and Zn2-GO.04-Cp 
respectively. The parameters are calculated and summarized in table 5-5. 
The XRD pattern for sample A-Zn2-IE (figure 5-28). Shows a shift of the peak at plane 
(003) to a lower 2θ of 4.5°, and a d-spacing expansion of 18.5 Å. After subtracting the 
brucite-like layer thickness (4.77 Å), it gives an interlayer space of 13.73 Å, suggesting 
the intercalation of the drug in a bi-layered arrangement [55][61][104]. The peak at (003) 
is broad and of low intensity, indicating disturbance of the layer stacking of the LDH 
[6][55]. The calculated d(110) is 1.53 Å, indicating no change in the brucite-like layer 
[61].  
 
Fig 5-28. XRD patterns of alendronate sodium (a), pristine LDH Zn2-Cp (b), and A-Zn2-IE (c). 
 
 
The XRD patterns of samples A-Zn2-G-IE and A-Zn2-GO-IE (figure 5-29), show no 
noticeable change of the d-spacing (8.7 and 8.5 Å respectively) compared to their 
precursors (8.6 and 8.8 Å respectively). After subtracting the brucite-like layer thickness 
(4.77 Å), it gives an interlayer distance of 3.8 and 4 Å respectively, which is equal to the 
size of the nitrate anion (4 Å). These findings suggests failure of drug exchange with 
nitrate anions. The reflections at (006), (012), and (110) are wide and of low intensity due 
to the disturbance in the interlayer anions during exchange [1][111]. The calculated 
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d(110) is 1.53 Å, same as that of the precursors indicating no change in the brucite-like 
layer [61]. 
 
Fig 5-29. XRD patterns of  alendronate sodium (a), Zn2-G.04-Cp (b), A-Zn2-G-IE (c), Zn2-GO.04-Cp (d), 
and A-Zn2-GO-IE (e). 
 
 
Table 5-5. Comparison between the parameters of the loaded samples prepared by ion-exchange, using 
metal cations ratio of 2:1 and their controls. 
 
 
 
 
Before drug loading After drug loading 
Sample 
precursor 
2θ 
(at 003 
plane) 
d-spacing  
(Å) 
Interlayer 
space  
(Å) 
Loaded  
Sample 
2θ 
(at 003 
plane) 
d-spacing 
(Å) 
Interlayer 
space  
(Å) 
  d 
(003) 
d 
(110) 
 d 
(003) 
d 
(110) 
Zn2-Cp 9.7° 9.1 1.53 4.30 A-Zn2-IE 4.5° 18.5 1.54 13.7 
Zn2-G.04-
Cp 
10.2° 8.6 1.53 3.89 
A-Zn2-G-
IE 
10.1° 8.76 1.53 3.99 
Zn2-GO.04-
Cp 
10.0° 8.8 1.53 4.00 
A-Zn2-
GO-IE 
10.6° 8.50 1.53 3.70 
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B- FTIR 
Figure 5-30, shows the FTIR spectra of A-Zn3-IE being compared to its precursor Zn3-
Cp and free alendronate sodium. The loaded system (A-Zn3-IE), shows the characteristic 
broad band at around 3440 cm
-1
 of pristine LDH, that is attributed to OH groups of the 
brucite-like layers, adsorbed water molecules, and the OH group of the free alendronate 
sodium [106][113]. This band overlaps with the stretching vibration band of N-H 
(primary amine) of the free alendronate sodium, that appears in the range of 3400-3250 
cm
-1 
[56][106][113]. The nitrate band at 1380 cm
-1 
of pristine LDH has noticeably 
decreased, indicating the displacement of the nitrate anions by alendronate sodium, with 
possible presence of some retained nitrate anions [113][120]. The free drug shows 
distinctive bands between 925 and 1238 cm
-1
, which attribute to the stretching vibrations 
of C-O and P=O bonds. These bands are shifted and overlapped to give a distinctive 
broad band at around 1110 cm
-1
 in the loaded sample, which suggests a hydrogen bond 
interaction with the LDH structure [106][121][122]. The vibration bands appearing at 
lower frequencies (428, 606, and 831 cm
-1
)  in the pristine LDH are assigned to the 
bending vibrations of the M-O and M-O-M bonds in the brucite-like layer [111]. These 
bands in the loaded samples are shifted (580 cm
-1
 and 966 cm 
-1
), suggesting a guest-host 
interaction between the drug and the OH groups of the brucite-like layers, which is also 
supported by the overlap of these band with that of the drug (1110 cm
-1
) [113][121][122]. 
All of these observations confirm the successful intercalation of the alendronate sodium 
into the LDH interlayer space as has been suggested by the XRD results [120].   
 
 Fig 5-30. FTIR spectra of A-Zn3-IE (a), Zn3-Cp (b), and alendronate sodium (c). 
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Figure 5-31 and 5-32, show the FTIR spectra of samples A-Zn3-G-IE and A-Zn3-GO-IE. 
Their XRD results have shown failure of intercalation, but the LDH stayed intact. 
Therefore, the LDH’s characteristic bands and other band features  appears in the FTIR 
pattern as follows:  
 OH broad band at around 3461cm
-1
.  
  Nitrate band at around 1363 cm
-1
.  
  C-O and P=O stretching vibrations of alendronate sodium at around 1110 cm
-1. 
  M-O and M-O-M bonds at their original frequencies at around 400, 600 and 800 
cm
-1
. 
The nitrate band intensity decreases, but did not completely disappear, which indicates 
the presence of  nitrate traces in the interlayers [113][120]. The decrease in the intensity 
is probably because of the loss of nitrates during the long contact with the solution. The 
failure of drug exchange is proven by the presence of the M-O and M-O-M bands at their 
original frequencies. However, the presence of the characteristic alendronate sodium 
band proves the presence of the drug in the system. The drug’s band is shifted from its 
original frequencies and overlapped, giving a single broad band at 1110 cm
-1
, suggesting 
a hydrogen bond interaction [106][121][122]. Therefore, the drug seem to be adsorbed on 
the surface of the brucite-like layers rather than  intercalated. However, one of the  M-O 
and M-O-M bands overlaps with the drug’s band at 964 cm-1 appears in sample A-Zn3-G-
IE, but not in A-Zn3-GO-IE, which indicates that the drug in case of A-Zn3-G-IE favors 
hydrogen bonding with the brucite-like layers rather than G, which is not the case with 
the A-Zn3-GO-IE, where the drug probably favors the  adsorption on the highly 
functionalized GO rather than the brucite-like layers. 
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 Fig 5-31. FTIR spectra of A-Zn3-G-IE (a), Zn3-G.04-Cp (b), and alendronate sodium (c). 
 
 Fig 5-32. FTIR spectra of A-Zn3-GO-IE (a), Zn3-GO.04-Cp (b), and alendronate sodium (c). 
 
Figure 5-33, shows the FTIR spectrum of sample A-Zn2-IE. It has same interpretation 
and band features as sample A-Zn3-IE, as follows: 
 OH broad band at around 3440 cm
-1
 of pristine LDH. 
 Nitrate nitrate band at around 1367 cm
-1
. 
 C-O and P=O stretching vibrations of alendronate sodium appears at 1114 cm
-1
. 
  M-O and M-O-M vibration bands of the brucite-like layer at 568, and 966 cm
-1
. 
 
c 
b 
 
 
a 
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The decrease of the nitrate band, is due to displacement with the drug, but with very 
small retained traces. The hydrogen bonding and the guest host interaction between the 
drug and the brucite-like layers, are supported by the overlapping and shift of the 
alendronate sodium band and the down shift of the M-O and M-O-M bands from their 
original frequencies [113][121][122]. 
 
 
 Fig 5-33. FTIR spectra of A-Zn2-IE (a), Zn2-Cp (b), and alendronate sodium (c). 
 
Figure 5-34 and 5-35, show the FTIR spectra of samples A-Zn2-G-IE and A-Zn2-GO-IE. 
They have same interpretation and band features as in samples A-Zn3-G-Cp and A-Zn3-
GO-Cp as follows: 
 OH broad band at around 3440 cm-1 of pristine LDH.  
 Nitrate band at 1384 cm-1. 
 C-O and P=O stretching vibrations bonds of alendronate sodium at around 1112 
cm
-1
. 
 M-O and M-O-M vibration bands at around 426, 600 and 800 cm-1. 
The nitrate band intensity is very noticeable, which indicates no displacement of the 
nitrate anions. The slight decrease in the band intensity is probably because of the loss of 
nitrates during the long contact with the solution as previously mentioned rather than 
being exchanged. The failure of drug exchange is proven by the presence of the M-O and 
M-O-M bands at their original frequencies. However, the characteristic broad band of 
alendronate sodium,  indicates its presence in the LDH system, suggested to be adsorbed 
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on the surface of the brucite-like layer via hydrogen bonding, supported by the 
overlapping and shifting of the drug’s band and the overlap of one of the M-O and M-O-
M bands with the drug’s band at 935 cm-1 and 962 cm-1 for A-Zn2-G-Cp and A-Zn2-GO-
Cp respectively [106][113][121][122].  
 
 
 
 Fig 5-34. FTIR spectra of A-Zn2-G-IE (a), Zn2-G.04-Cp (b), and alendronate sodium (c). 
 
 Fig 5-35. FTIR spectra of A-Zn2-GO-IE (a), Zn2-GO.04-Cp (b), and alendronate sodium (c). 
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5.5. Determination of drug loading and release profile 
5.5.1. Drug loading:  
The amount of drug loaded was calculated for the successfully loaded samples, and the 
particle size was measured for such samples in order to investigate the relationship 
between the particle size and the amount of loaded drug. There are some suggested 
outcomes that could be obtained from such relationship: the particle size might have an 
effect on the surface area available for loading (inversely proportional), it could be an 
indication to how the drug is loaded (intercalation or surface adsorption), or show any 
particles’ agglomerates. A summary of the loading percentages and particle size values 
are shown in table (5-6 and 5-7). 
 In samples prepared by co-precipitation using M
2+/
M
3+
 ratio 3:1 (figure 5-36, blue). The 
loaded amount of alendronate sodium in sample A-Zn3-Cp is determined to be 25.36 % 
w/w (amount of loaded drug (mg) per 100 mg of the total hybrid), this loaded amount 
includes both intercalated drug and that adsorbed on the surface of the brucite-like layers. 
While the determined intercalated and adsorbed amounts in A-Zn3-G-Cp and A-Zn3-GO-
Cp are 36% and 36.6 % w/w respectively. The G/GO-LDH hybrid samples have shown 
an increase in the percentage loaded, due to the increase of the surface available for drug 
adsorption provided by the G or GO. Therefore, for the co-precipitated samples, the 
effect of G and GO on the drug loading was noticeable. However, the size differences 
between the three samples 656.1, 765.2 and 610.0 nm respectively (table 5-6) are limited, 
which indicates that loading via intercalation is predominant. 
As for samples prepared by co-precipitation using M
2+/
M
3+
 ratio 2:1 (figure 5-36, 
orange): A-Zn2-Cp, A-Zn2-G-Cp and Zn2-GO-Cp, have shown low percentages of 
loaded drug: 15.26%, 12.28%, and 16.4 % w/w respectively. These low loading 
percentages are due to the collapse of the LDH structure, leading to no intercalation of 
the drug. Loaded drug amounts are believed to be mostly surface adsorbed on the 
exfoliated brucite-like layers, and/or on G and GO. The size difference between that of 
A-Zn2-Cp and A-Zn2-GO-Cp is minimal (386.4 and 336.9 nm respectively), but that of 
A-Zn2-G-Cp (1273.4 nm) is noticeably larger. This might be due to G agglomerating by 
π-π stacking, forming large sized particles; without necessarily being accompanied by 
adsorption of the drug on the G surface, because these agglomerate hinders the drug to 
reach the surface of the G or LDH.  
 
 
96 
 
 
As an overall findings, the hybrid samples prepared by LDH of M
2+
/M
3+
 ratio 3:1(A-Zn3-
Cp, A-Zn3-G-Cp and A-Zn3-GO-Cp), have higher loading percentages compared to 
those prepared by 2:1 ratio (A-Zn2-Cp, A-Zn2-G-Cp and A-Zn2-GO-Cp), with a further 
increase in the presence of G or GO.  
 
 
Table 5-6. The drug loaded amounts and  particle sizes of samples prepared by co-precipitation using 
M
2+/
M
3+
 ratios 2:1 and 3:1 respectively. 
Sample 
Loading 
(% w/w) 
Size 
(nm) 
A-Zn2-Cp 15.3 386.4 ± 85 
A-Zn2-G-Cp 16.4 1273.4± 261 
A-Zn2-GO-Cp 12.4 336.9± 3 
A-Zn3-Cp 25.4 656.1± 16 
A-Zn3-G-Cp 36.0 765.2± 43 
A-Zn3-GO-Cp 36.6 610.0± 16 
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Fig 5-36. A plot of the percentages of the drug loaded (% w/w) versus particle sizes (nm), to compare 
between the loading percentages, particle sizes and loading-size relationship, among samples 
prepared by same M
2+/
M
3+
 ratio, 3:1 (blue) or 2:1 (orange), and between both ratios. 
 
As for the ion-exchange samples A-Zn3-IE (figure 5-37, green) and A-Zn2-IE (figure 5-
37, red), which are prepared using LDH of M
2+/
M
3+
 ratio 3:1 and 2:1 respectively, the 
loaded percentages are 50.5% and 51 % w/w respectively. Both samples almost have the 
same loading values, in spite of their size difference (380.9 and 853.0 nm respectively), 
which is very noticeable, suggesting that loading is primarily via intercalation and the 
size difference is rather due to particles’ agglomeration. The loading percentage is high 
compared to their equivalents in the co-precipitation samples, indicating that the nitrate 
groups have been largely exchanged during the long contact time with the drug.  
As for samples A-Zn3-G-IE (figure 5-37, green) and A-Zn2-G-IE (figure 5-37, red), the 
loading percentages are 22.5% and 57.3 % w/w respectively. As discussed previously in 
the XRD results, these two samples have shown loss in the ordered arrangement of the 
brucite-like layers, therefore the drug loading is believed to primarily be by surface 
adsorption, with higher loading percentage in sample A-Zn2-G-IE, because the LDH of 
M
2+
/M
3+
 ratio of 2:1 possesses more positive charges, and hence attracting more drug 
anions onto its surface. This explains the difference in drug loaded amount in spite of the 
comparable particle size (568.8 and 562.8 nm respectively).  
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Finally, samples A-Zn3-GO-IE and A-Zn2-GO-IE show almost the same sizes, 299.7 and 
290.5 nm respectively and loading percentages: 24 and 25.9 % w/w with slight increase 
in the latter because of the high positive charges (M
2+
/M
3+
 ratio is 2:1). The relatively low 
loading % in both is attributed to the presence of GO, which may be contributing to the 
neutralization of  charges of the brucite-like layers limiting drug adsorption on the LDH 
surface.    
As an overall findings, the samples prepared using LDH of M
2+
/M
3+
 ratio 2:1, and their 
corresponding in 3:1 samples, have relatively comparable loading percentages, except A-
Zn2-G-IE, which has high loading percentage than A-Zn3-G-IE, due to the high charge 
density as previously discussed. They all have comparable sizes as well except A-Zn2-IE, 
which has bigger size than A-Zn3-IE, which could be due to agglomeration caused by the 
high charge density. However, hybrids with GO (A-Zn2-GO-IE, A-Zn3-GO-IE) have 
shown the lowest loaded amount, due to GO competing to neutralize the brucite-like 
layers as  previously discussed.  
 
 
Table 5-7. The drug loaded amounts and particle sizes of samples prepared by ion-exchange using M
2+/
M
3+
 
ratios 2:1 and 3:1 respectively. 
Sample 
Loading  
(% w/w) 
Size  
(nm) 
A-Zn2-IE 51.0 853.0± 19 
A-Zn2-G-IE 57.3 562.8± 24 
A-Zn2-GO-IE 25.9 290.5± 3 
A-Zn3-IE 50.5 380.9± 1 
A-Zn3-G-IE 22.4 568.8± 32 
A-Zn3-GO-IE 24.0 299.7± 0 
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Fig 5-37. A plot of the percentages of the drug loaded (% w/w) versus particle sizes (nm), to compare 
between the loading percentages, particle sizes and loading-size relationship, among samples 
prepared by same M
2+/
M
3+
 ratio, 3:1 (green) or 2:1 (red), and between both ratios. 
System A-Zn2-IE, A-Zn2-G-IE and A-Zn3-IE, are with the highest loaded drug amounts 
(57.3, 51 and 50.5 mg respectively), which are equivalent to 1.3, 1.04 and 1 mg of 
alendronate sodium in each mg of the system (drug-LDH, drug-G-LDH and drug-LDH 
respectively), either adsorbed on the LDH surface or intercalated. These amounts of drug 
loaded are higher than that reported in the previously mentioned literature reported by 
Chakraborti (2011) [124], where the alendronate sodium intercalated in Mg/Al LDH 
system was 0.6 mg/mg LDH [124]. 
 
5.5.2. Drug release profile: 
Based on the previously discussed XRD and FTIR results, the release profile of the 
samples that have shown successful loading via intercalation was studied in water for a 
period of 24 hours according to the USP for alendronate sodium. While the samples that 
have shown drug loading via surface adsorption were excluded from this study, as would 
give a burst release rather than sustained. 
Figure 5-38 plots the percentage of drug released from the systems prepared by co-
precipitation using M
2+/
M
3+
 ratio 3:1: A-Zn3-Cp, A-Zn3-G-Cp and A-Zn3-GO-Cp versus 
time in hours. The three systems show a highly sustained release profile over 24 hours, 
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giving a slight increase at the end with a total release of 3.5%, 4.2% and 2.9%, from A-
Zn3-Cp, A-Zn3-G-Cp and A-Zn3-GO-Cp hybrid systems respectively. This is attributed 
to the strong attachment of the positively charged brucite-like layers to the intercalated 
drug guest. The sample with the lowest total release percentage is  A-Zn3-GO-Cp is the, 
because GO has a highl functionalized platform that attracts the drug onto its surface 
through hydrogen bonding, slightly hindering the release of the drug when compared to 
the other two samples. Followed by Sample A-Zn3-Cp with a slightly higher total release 
percentage, because it has less charge density, where only the brucite-like layer is the 
surface attracting the drug, facilitating the release. And finally sample A-Zn3-G-Cp, with 
the highest total release percentage, because  some of the drug is attached to the surface 
of the brucite-like layer, and others are weakly attached to the surface of G 
(unfunctinalized), therefore, the drug is easily released.    
 
  Fig 5-38. Release profile of A-Zn3-Cp (blue), A-Zn3-G-Cp (red) and A-Zn3-GO-Cp 
(green). 
Figure 5-39 shows the release profile of the samples prepared by ion exchange: A-Zn2-IE 
and A-Zn3-IE, of metal cations ratio 3:1 and 2:1 respectively. The release profile shows a 
sustained release over 24 hours, giving a total release percentage of 2.1% and 2.5%. The 
total release percentage of sample A-Zn3-IE is slightly higher, attributed to the fact that 
the LDH with M
2+
/M
3+
 ratio of 3:1 has lower positive charge density than that of  sample 
A-Zn2-IE (M
2+
/M
3+
, 2:1), and therefore, is more likely to lose the hosted drug easily. But 
in case of A-Zn2-IE, the drug is more attached to the brucite-like layer, hindering it 
release.  
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Fig 5-39. Release profile of A-Zn2-IE (blue), and A-Zn3-IE (red). 
 
Table 5-8. Amounst and percentages of drug released from 100 mg of hybrid system at 24 hr. 
 
Table 5-8 presents a summary of the amounts and percentages of drug released at 24 hr 
from 100 mg of the hybrid system. These results have been compared to literature 
reported by Chakraborti [124]. The literature showed burst release of ≈45 % over the 6 
hour, while that of the systems in this research work, the release over the 6 hours is 
ranging between 1.7-2.9 %, which continue with a sustained behavior for 24 hrs with 
maximum drug release ranging between 2.1-4.2 %. As for the one reported in literature 
had shown a sustained release over 6 days with approximate release of 80 %. 
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Time interval 
(hr) 
Amount released from 100 mg 
of hybrid sample at 24 hr 
(mg) 
% Released from 100 mg 
of hybrid sample at 24 hr 
 
A-Zn3-Cp 0.90 3.5± 0.009 
 
A-Zn3-G-Cp 1.52 
 
4.2±0.034 
 
A-Zn3-GO-Cp 1.08 
 
2.9±0.003 
 
A-Zn2-IE 1.07 
 
2.1±0.002 
 
A-Zn3-IE 1.28 
 
2.5±0.013 
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5.6. Summary of the work and results 
The work is summarized in the following points: 
 G was oxidized to GO sheets by Hummers method and characterized by XRD, 
FTIR and SEM. 
 
 Zn-Al-NO3 LDH controls of M
2+
/M
3+
 ratios 2:1 and 3:1 were prepared for 
comparison with the loaded corresponding samples. 
 
 Different amounts of G and GO were incorporated with the LDHs by co-
precipitation, and the crystallinity of the resulting nanocomposites investigated. 
The 2 % w/w had the best LDH crystallinity, and therefore was chosen as the 
amount of G and GO to be incorporated. 
 
 The masses of G and GO corresponding to a content of 2 % w/w in the 
nanocomposite, were dispersed in water of different volumes to result in 
suspensions of different concentrations. This was for the purpose of investigating 
whether the volume of water in which the G and GO were dispersed had any 
effect on the composition and crystallinity of the final LDH-G and LDH-GO 
nanocomposites. Different dispersion concentrations gave comparable results for 
crystallinity. Therefore, the lowest dispersion concentration was chosen (highest 
volume of water) to ensure better G and GO dispersion. 
 
 The formed nanocomposites were loaded with alendronate sodium by two 
methods: co-precipitation and ion exchange. They were then characterized by 
XRD and FTIR, where some have showed loading via intercalation and 
adsorption. 
 
 Only samples with successful intercalation were tested for their release profile. 
These exhibited sustained release over 24 hours. 
 
 
 
 The prepared samples and a summary of their results are summarized in the 
following table (5-9). 
103 
 
 
Zn-Al-NO3 (M
2+
/M
3+
, 2:1) 
Loaded by co-precipitation Loaded by ion-exchange 
Samples Loading method 
Loaded 
amount 
(% 
w/w) 
Total drug 
released 
over 24 hr 
(% of total 
load) 
Samples Loading method 
Loaded 
amount 
(% 
w/w) 
Total drug 
released 
over 24 hr 
(% of total 
load) 
A-Zn2-Cp 
Primarily via Surface adsorption on 
LDH layers 
15.3 
Drug not 
intercalated 
A-Zn2-IE Primarily via intercalation in 
bi-layer arrangement and 
surface adsorption on LDH 
51.0 2.1 
A-Zn2-G-Cp Primarily via Surface adsorption on 
LDH layers and G 
16.4 
Drug not 
intercalated 
A-Zn2-G-IE Primarily via surface 
adsorption on LDH and G 
57.3 
Drug not 
intercalated 
A-Zn2-GO-Cp Primarily via Surface adsorption on 
LDH layers and GO 
12.4 
Drug not 
intercalated 
A-Zn2-GO-IE Primarily via surface 
adsorption on LDH and GO 25.9 
Drug not 
intercalated 
Zn-Al-NO3 ( M
2+
/M
3+
, 3:1) 
         Loaded by co-precipitation Loaded by ion-exchange 
Samples Loading method 
Loaded 
amount 
(%w/w) 
Total drug 
released 
over 24 hr 
(% of total 
load) 
Samples Loading method 
Loaded 
amount 
(%w/w) 
Total released 
Over 24 hr 
(% of total 
load) 
A-Zn3-Cp Primarily via intercalation in a  
bi-layer arrangement and surface 
adsorption on LDH 
25.4 3.5 
A-Zn3-IE Primarily via intercalation in 
a bi-layer arrangement and 
surface adsorption on LDH 
50.5 2.5 
A-Zn3-G-Cp Primarily via intercalation in a  
bi-layer arrangement and surface 
adsorption LDH and G 
36.0 4.2 
A-Zn3-G-IE Primarily via surface 
adsorption on LDH and G 22.4 
Drug not 
intercalated 
A-Zn3-GO-Cp Primarily via intercalation in a  
bi-layer arrangement and surface 
adsorption LDH and GO 
36.6 2.9 
A-Zn3-GO-IE Primarily via surface 
adsorption on LDH and GO 24.0 
Drug not 
intercalated 
Table 5-9. All prepared samples and their results, with respect to the following aspects: drug loading mechanism, loaded amount (% w/w), and the total drug 
released at 24 hr (% of total load). 
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Table 5-10. Schematic presentation of the drug loading mechanism in the prepared loaded samples, where each component is represented as follows:  
LDH( ), Interlayer nitrate anions ( ), drug anions ( ), G ( ), and GO( ). 
 
Co-precipitation prepared samples  
Sample Loading 
mechanism 
Schematic presentation 
A-Zn3-Cp Primarily by 
intercalation in a  
bi-layer arrangement 
and surface 
adsorption on LDH. 
 
A-Zn3-G-Cp,  Primarily by 
intercalation in a  
bi-layer arrangement 
and surface 
adsorption LDH and 
G. 
 
 A-Zn3-Go-Cp Primarily by 
intercalation in a  
bi-layer arrangement 
and surface 
adsorption LDH and 
GO. 
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A-Zn2-Cp Primarily by surface 
adsorption on LDH 
layers 
 
A-Zn2-G-Cp Primarily by surface 
adsorption on LDH 
layers and G 
 
A-Zn2-GO-Cp Primarily by surface 
adsorption on LDH 
layers and GO 
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Ion-Exchange prepared samples 
A-Zn2-IE, and 
A-Zn3-IE 
Primarily by 
intercalation in bi-
layer arrangement 
and surface 
adsorption on LDH 
 
A-Zn2-G-IE, 
and A-Zn3-G-IE 
Primarily by surface 
adsorption on LDH 
and G 
 
A-Zn2-GO-IE, 
and A-Zn3-GO-
IE 
Primarily by surface 
adsorption on LDH 
and GO 
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Chapter 6. 
Conclusion and Future Work 
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6. Conclusion and Future work 
 
6.1. Conclusion 
Nanocomposites of G/GO-Zn-Al LDH were prepared, with 2% w/w of G and GO 
(prepared by modified Hummers method) incorporated with two different M
2+
/M
3+
 ratios 
of LDH (2:1 and 3:1), and their use as potential drug delivery systems was tested. The 
samples were tested for the loading and release of alendronate sodium, which is a nBP 
drug, typically with low bioavailability (< 1%), and gastrointestinal adverse effects.  
The nanocomposites, as well as the blank LDH samples, were loaded with alendronate 
sodium with two methods: co-precipitation and ion-exchange, and they were then 
characterized by XRD and FTIR. The samples that showed successful intercalation of the 
drug in bi-layered arrangement are : co-precipitation samples prepared using M
2+
/M
3+
 of 
3:1 (A-Zn3-Cp, A-Zn3-G-Cp and A-Zn3-GO-Cp), and ion exchange samples with either 
M
2+
/M
3+
  of 2:1 or 3:1, with no G or GO (A-Zn2-IE and A-Zn3-IE).  Their drug loading 
amounts were found to be  25.4, 36.0, 36.6, 51.0, and 50.5 % w/w respectively. The G 
and GO had a noticeable effect on the amount of drug loaded in the co-precipitation 
samples (51 and 50.0 % respectively). The release of the drug from these systems were 
sustained showing almost a plateau over 24 hours, with minimum amounts released, and 
a total release percentages after 24 hr ranging from 2.1% to 4.2 % which are equivalent to 
1.07 and 1.5 mg of the drug respectively, released from 100 mg of the system.  
For samples that did not show successful intercalation (A-Zn2-Cp, A-Zn2-G-Cp, A-Zn2-
GO-Cp, A-Zn2-G-IE, A-Zn2-GO-IE, A-Zn3-G-IE, and A-Zn3-GO-IE), drug loading was 
by surface adsorption on the LDH brucite-like layers and G/GO. Their corresponding 
drug loading amounts are 15.3, 16.4, 12.4, 57.3, 25.9, 22.4, and 24 % w/w respectively. 
Samples prepared by co-precipitation using M
2+
/M
3+
 of 2:1 (A-Zn2-Cp, A-Zn2-G-Cp, 
and A-Zn2-GO-Cp) were with the lowest loaded amount of the drug, because of the 
collapse of the LDH layered structure. While samples prepared by ion-exchange, 
incorporating G/GO (A-Zn3-G-IE, A-Zn3-GO-IE, A-Zn2-G-IE and A-Zn2-GO-IE), 
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showed the highest loading, because of the long contact of the hybrid with the drug 
solution allowing more drug to be adsorbed on the surface. 
Findings show that two systems are meeting the criteria of high drug loading and 
sustained release behavior. The systems are A-Zn3-G-Cp and A-Zn3-GO-Cp, with loaded 
drug amounts of 36 and 36.5 % w/w and sustained release over 24 hrs with total amount 
released 1.52 and 1.08 mg, which are the highest among samples.  
 
6.2. Future work 
Future work would focus on the following aspect: 
 Molecular simulation, to predict the arrangement of the drug molecules in the 
LDH interlayers, as well as those adsorbed on the surface.  
 
 To perform a mucus adsorption and a cellular uptake studies to investigate the 
permeability of the hybrid through the GIT mucus membrane, and its uptake by 
the bone cells.  
 
 Toxicity test of the hybrid to identify limit of toxicity for oral intake of the 
required dose. 
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Appendix A: Calibration curves 
 
 
Calibration curve of Alendronate sodium in simulated gastric fluid for the loading 
determination test.  
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Calibration curve of Alendronate sodium in de-ionized water for the release test. 
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